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Sarah Marie Wilson 
INVOLVEMENT OF COLLAPSIN RESPONSE MEDIATOR PROTEIN 2 IN 
POSTTRAUMATIC SPROUTING IN ACQUIRED EPILEPSY 
 
 Posttraumatic epilepsy, the development of temporal lobe epilepsy (TLE) 
following traumatic brain injury, accounts for 20% of symptomatic epilepsy.  
Reorganization of mossy fibers within the hippocampus is a common pathological 
finding of TLE.  Normal mossy fibers project into the CA3 region of the hippocampus 
where they form synapses with pyramidal cells.  During TLE, mossy fibers are observed 
to innervate the inner molecular layer where they synapse onto the dendrites of other 
dentate granule cells, leading to the formation of recurrent excitatory circuits.  To date, 
the molecular mechanisms contributing to mossy fiber sprouting are relatively unknown.   
 Recent focus has centered on the involvement of tropomycin-related kinase 
receptor B (TrkB), which culminates in glycogen synthase kinase 3β (GSK3β) 
inactivation.  As the neurite outgrowth promoting collapsin response mediator protein 2 
(CRMP2) is rendered inactive by GSK3β phosphorylation, events leading to inactivation 
of GSK3β should therefore increase CRMP2 activity.  To determine the involvement of 
CRMP2 in mossy fiber sprouting, I developed a novel tool ((S)-LCM) for selectively 
targeting the ability of CRMP2 to enhance tubulin polymerization.  Using (S)-LCM, it 
was demonstrated that increased neurite outgrowth following GSK3β inactivation is 
CRMP2 dependent.  Importantly, TBI led to a decrease in GSK3β-phosphorylated 
CRMP2 within 24 hours which was secondary to the inactivation of GSK3β.  The loss of 
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GSK3β-phosphorylated CRMP2 was maintained even at 4 weeks post-injury, despite the 
transience of GSK3β-inactivation. 
 Based on previous work, it was hypothesized that activity-dependent mechanisms 
may be responsible for the sustained loss of CRMP2 phosphorylation.  Activity-
dependent regulation of GSK3β-phosphorylated CRMP2 levels was observed that was 
attributed to a loss of priming by cyclin dependent kinase 5 (CDK5), which is required 
for subsequent phosphorylation by GSK3β.  It was confirmed that the loss of GSK3β-
phosphorylated CRMP2 at 4 weeks post-injury was likely due to decreased 
phosphorylation by CDK5.  As TBI resulted in a sustained increase in CRMP2 activity, I 
attempted to prevent mossy fiber sprouting by targeting CRMP2 in vivo following TBI.  
While (S)-LCM treatment dramatically reduced mossy fiber sprouting following TBI, it 
did not differ significantly from vehicle-treated animals.  Therefore, the necessity of 
CRMP2 in mossy fiber sprouting following TBI remains unknown. 
 
Gerry S. Oxford, Ph.D. 
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1.1. Temporal Lobe Epilepsy: A Progressive, Acquired Phenomenon 
Background 
Nearly 2.3 million people in the United States alone are burdened by epilepsy 
(CDC, 2012), a neurological condition classified by spontaneously recurring seizures 
(Goddard et al., 1969), with an estimated 150,000 more diagnosed each year (Hirtz et al., 
2007, (IOM), 2012).  Outside of the United States, worldwide prevalence may reach as 
high as 6% in undeveloped countries (Burneo et al., 2005, Carpio and Hauser, 2009).  It 
is estimated that nearly half of epilepsy cases are classified as complex partial seizures, 
the majority of which originate from foci within the temporal lobe (Hauser and Kurland, 
1975, Manford et al., 1992a, b, Larner, 1995, Panayiotopoulos, 2005).  While early 
symptoms of temporal lobe epilepsy (TLE) are well controlled with currently available 
anti-epileptic treatment strategies, as the disease progresses as many as 30% of patients 
develop medically-intractable seizures (Willmore, 1992, Wieser and Hane, 2004, Loscher 
and Schmidt, 2011).  The basis of this advancement to an intractable state is likely to 
stem from the progressive nature of the disease rather than issues of pharmacological 
tolerance (Sutula, 2004).   Unfortunately, while recent advances in antiepileptic drugs 
(AEDs) have reduced the risk of serious contraindications associated with first and 
second generation AEDs, they have not proven to be more efficacious in the treatment 
and/or prevention of epilepsy symptoms (Rogawski and Loscher, 2004b, a, Loscher and 
Schmidt, 2011, O'Dell et al., 2012).  The lack of advancement in the treatment of TLE 
may be attributed to gaps in understanding of the mechanisms underlying its etiology.     
Investigation of post-mortem tissue samples from TLE patients has highlighted 
various anatomical changes occurring within the hippocampus that may provide a 
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framework for understanding potential mechanisms (Margerison and Corsellis, 1966, de 
Lanerolle et al., 1989, Masukawa et al., 1989, Represa et al., 1989, Sutula et al., 1989, 
Geddes et al., 1990, Houser, 1990, Houser et al., 1990, Babb, 1991, Babb et al., 1991, 
McDonald et al., 1991, Masukawa et al., 1992).  The most common pathological finding 
is the occurrence of hippocampal sclerosis, characterized by fibrous gliosis and overall 
atrophy of the hippocampal formation.  These changes likely stem from selective loss of 
pyramidal cells within subregions CA1, CA3, and the hilus, that are not observed within 
the CA2 subregion or the granule cell layer (Margerison and Corsellis, 1966).  
Microscopic changes include alterations in excitatory and inhibitory neurotransmitter 
receptor expression, levels of peptidergic signaling molecules, and dramatic 
reorganization of both dendritic and axonal projections.  Regional increases in ionic 
glutamate receptors have been observed within subregions CA1 and CA3, the entorhinal 
cortex, and the dentate gyrus (Represa et al., 1989, Geddes et al., 1990, McDonald et al., 
1991).  Alternatively, expression of GABAA receptors was decreased within subregions 
CA1 and CA4 (McDonald et al., 1991).  Decreases in somatostatin and neuropeptide Y 
immunoreactivity within the hilus suggest an overall loss of inhibitory interneurons 
within this region (de Lanerolle et al., 1989, Robbins et al., 1991).  Perhaps in 
compensation of this loss, synaptic reorganization of spared GABAergic and peptidergic 
interneurons was also observed (de Lanerolle et al., 1989, Masukawa et al., 1989).  A 
more dramatic example of circuit reorganization was observed in the axons of dentate 
granule cells.  Axon collaterals from these cells were observed aberrantly innervating the 
supragranular layer of the dentate gyrus (Sutula et al., 1989, Houser, 1990, Babb et al., 
1991, Masukawa et al., 1992).  Importantly, the majority of these observations are 
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recapitulated in animal models of TLE (Sutula et al., 1988, Mello et al., 1993, Frotscher 
et al., 2006).  However, the contribution of these gross hippocampal alterations to the 
initiation and/or progression of TLE is not well understood.  Epilepsy, as a whole, is a 
complex, progressive disorder (Larner, 1995, Sutula, 2004).  As such, its mechanistic 
foundation is unlikely to be ascribed to one underlying factor.  It is logical to assume that 
many of the aforementioned changes, in combination with one another, attribute to the 
manifestation of TLE and its symptoms.    In fact, seizures may not simply be 
symptomatic expressions, but rather, contributing factors in the perpetuation of the 
disease (Goddard et al., 1969, Sutula, 2004).   
In many patients, TLE is initiated by a traumatic event such as traumatic brain 
injury (TBI), febrile seizures, status epilepticus (SE), tumors, stroke, or infection 
(Kharatishvili and Pitkanen, 2010, Yang et al., 2010b, O'Dell et al., 2012).  These events 
are often followed by an asymptomatic latency period lasting upwards of 10 years prior 
to the development of spontaneous recurring seizures (de Lanerolle et al., 2003, Sharma 
et al., 2007, Yang et al., 2010b).  That these arguably diverse insults can lead to a similar 
phenotype suggests the possibility of shared epileptogenic mechanisms.  Posttraumatic 
epilepsy (PTE), the development of TLE following TBI, accounts for 20% of 
symptomatic epilepsy (Agrawal et al., 2006).  The risk of developing epilepsy following 
TBI is directly related to the severity of the injury, with relative risk increasing as much 
as 29-fold following severe TBI (Herman, 2002).  While it is difficult to predict whether 
an individual will develop epilepsy following injury, key risk factors include skull 
fracture, dural penetration, intracranial hematoma, and prolonged loss of consciousness 
(Jennett and Lewin, 1960, Annegers et al., 1998, Asikainen et al., 1999, Englander et al., 
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2003).  While it has been suggested that the initial neuronal injury is the underlying cause 
of progressive syndromes such as epilepsy (Mathern et al., 1996, Mathern et al., 2002), 
the prevailing theory proposes that the initial injury is a “self-limiting” event that leads to 
slowly evolving secondary changes (Sutula, 2004).  This secondary damage refers to 
neurodegeneration, neurogenesis, gliosis, demyelination, vascular damage, axonal 
sprouting, and angiogenesis (Reilly, 2001, Thompson et al., 2005, Pitkanen and 
McIntosh, 2006), which, in combination, may alter neuronal circuits and render them 
vulnerable to spontaneous synchronization (Sutula, 2004).  Emphasis has recently been 
placed on identifying potential prophylactic intervention strategies that, when given 
following TBI, may prevent the development of PTE.  Unfortunately, classical AEDs do 
not appear to have an anti-epileptogenic effect when administered following TBI in 
humans (Temkin, 2009).  Additionally, spontaneous seizures occurring more than 1 week 
following injury are rarely used as outcome measures in preclinical TBI trails (Pitkänen 
and Lukasiuk, 2009).  Therefore, much of the recent advancements have come from 
studies employing animal models. 
Animal Models 
The first animal model of TLE, developed in 1969, was based on the theory that seizures 
are self-perpetuating (Goddard et al., 1969).  The model involves repeated subconvulsant 
current injections into the limbic structures, such as the amygdala or the hippocampus.  
At first, the injections cause no behavioral response.  However, with repeated injections 
the previously subconvulsant currents elicit class V behavioral seizures, characterized by 
generalized tonic-clonic activity with loss of postural tone (Racine, 1972).  This process 
is known as “kindling” (Goddard et al., 1969), and remains a popular model for studies of 
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epileptogenesis.  Another commonly used model involves induction of limbic SE through 
either electrical stimulation or the use of chemical agents, followed by sustained 
electrographic discharges in limbic structures (Turski et al., 1983, Turski et al., 1984, 
Mazarati and Sankar, 2006, Mazarati et al., 2006).  This model involves three distinct 
stages: (1) an hours-long episode of sustained SE, (2) a days to weeks-long asymptomatic 
latent period, and (3) gradual development and progressive increase of spontaneously 
recurring seizures (Dudek et al., 2002, Dudek et al., 2006).  Interestingly, the evolution of 
spontaneous seizures following SE mirrors behavioral and electrographic milestones of 
kindling (Dudek et al., 2006).  As the last stage is often permanent, this model is 
exceptionally appropriate for modeling a chronic epileptic state following an apparent 
latent period, as seen in human patients.  While a variety of models exist for studying TBI 
in rodents, only a few of them have been characterized for the study of PTE (Pitkanen et 
al., 2006).  Most TBI models fall into one of the following categories: focal injury 
models, diffuse brain injury models, or mixed models of focal and diffuse injury (Cernak, 
2005, Morales et al., 2005).  In these models, spontaneous injury-related seizures can be 
observed within the early phase (< 1wk) following injury (Nilsson et al., 1994, Williams 
et al., 2005, Kharatishvili et al., 2006, Williams et al., 2006).  During this phase, 
increasing hyperexcitability is also observed within the hippocampus (Lowenstein et al., 
1992, Coulter et al., 1996, Toth et al., 1997, Reeves et al., 2000, Santhakumar et al., 
2001, Akasu et al., 2002, Witgen et al., 2005, Tran et al., 2006, Griesemer and Mautes, 
2007).  More convincing evidence of epileptogenesis is found during the late phase (> 1 
wk) followng injury (Pitkänen et al., 2009).  Hyperexcitability appears to be chronically 
maintained within the cortex and hippocampus (Santhakumar et al., 2001).  A reduction 
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in the response threshold to proconvulsant stimuli is also observed several weeks 
following injury (Golarai et al., 2001, Statler et al., 2008).  Most importantly, the 
emergence of spontaneous seizures can be observed starting at 7 weeks following injury 
(D'Ambrosio et al., 2004, D'Ambrosio et al., 2005, Kharatishvili et al., 2006).  Within 1 
year, it was estimated that epileptogenesis occurred in 40-50% of the animals receiving 
severe, non-penetrating TBI (Kharatishvili et al., 2006).  Recent work suggests focal 
injury models are more likely to promote epileptogenesis (Volman et al., 2011).  
Histological analysis following TBI in these models yields changes reminiscent of those 
found in human TLE patients (Golarai et al., 2001, Thompson et al., 2005, Kharatishvili 
et al., 2006, Pitkanen et al., 2006, Pitkanen and McIntosh, 2006, Statler et al., 2008, Hunt 
et al., 2009).  One of the more striking alterations consistently observed following injury 
is the aberrant sprouting of the dentate mossy fibers. 
1.2. Mossy Fiber Sprouting 
Background 
Projecting through the hilus to the proximal dendrites of pyramidal cells within 
the CA3 subregion, the unmyelinated axonal projections of dentate granule cells are 
collectively referred to as mossy fibers (Golgi, 1886, Ramón y Cajal, 1893).  By linking 
dentate granule cells with CA3 pyramidal cells, these projections form the second link in 
the hippocampal trisynaptic pathway that also includes the perforant path and the 
Schaffer collaterals, linking the entorhinal cortex to the dentate granule cells and the CA3 
pyramidal cells to the CA1 pyramidal cells, respectively (Andersen et al., 1969).  In 
addition to forming synaptic connections with CA3 pyramidal cells, collateral branches 
also synapse with a variety of neurons within the hilus, including interneurons (Blackstad 
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and Kjaerheim, 1961).  In depth analysis reveals that a single mossy fiber makes 
approximately 120-150 excitatory synaptic connections with hilar interneurons, 7-12 
large terminal contacts with hilar mossy cells, and 11-18 connections with the dendrites 
of CA3 pyramidal cells (Claiborne et al., 1986, Acsady et al., 1998).  Mossy fibers are 
predominantly glutamatergic (Gutiérrez et al., 2003); however, they have also been 
observed to release the opioid peptide dynorphin as well as the inhibitory 
neurotransmitter GABA (Walker et al., 2001).  Aberrant growth of the mossy fiber 
collaterals into the inner molecular layer is frequently observed in animal models on 
TLE, as well as in post-mortem tissue samples from human TLE patients (Figure 1.1) 
(Sutula et al., 1988, Sutula et al., 1989, Houser, 1990, Babb et al., 1991, Masukawa et al., 
1992, Mello et al., 1993, Frotscher et al., 2006).  The extent of aberrant mossy fiber 
sprouting is easily identified due to their high amount of chelatable zinc which can be 
visualized via a silver-sulfide staining method (Timm, 1958, Zimmer, 1973).  
Interestingly, mossy fiber sprouting can be elicited in response to TBI, status epilepticus, 
and repeated seizure activity (Sutula et al., 1988, Represa et al., 1989, Steward, 1992, 
Sutula et al., 1998, Golarai et al., 2001).   
Lesion-induced sprouting 
The hippocampus in general is particularly sensitive to CNS injury (Colicos et al., 
1996, Yakovlev et al., 1997).  In the case of TBI, injury to neuronal circuits can come 
directly from the injury, as in the case of penetrating injuries, or indirectly through axonal 
shearing and stretching that occurs with acceleration and deceleration of the brain 
(Povlishock and Katz, 2005).  Circuit reorganization following injury is thought to be a  
9 
 
  
Figure 1.1.  Representation of mossy fiber sprouting.  A typical granule cell (black) 
extends apical dendrites from the soma in the granule cell layer (GCL) into the inner 
molecular layer (IML).  Granule cells axons project through the hilus (DH) to synapse on 
pyramidal cells within the pyramidal cell layer (PCL) of the CA3 region, forming the mossy 
fiber projection.  During mossy fiber sprouting (red), axon collaterals of dentate granule cells 
branch within the DH (green arrow) and extend into the IML where they form synapses with 
the dendrites of other granule cells (blue arrow).   
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compensatory mechanism, through which the lost functions of damaged regions are 
potentially restored by uninjured regions (Xerri et al., 1998, Ramirez, 2001).  The 
functions of the damaged regions are potentially compensated for by homologous regions 
of the contralateral hemisphere, spared regions of the ipsilateral hemisphere, or lower-
level structures (Stein, 1998).  Post-lesion sprouting is classified as either homotypic or 
heterotypic in nature (Ramirez, 2001).  Homotypic reorganization involves sprouting of 
pathways that share functional characteristics with the injured pathway, such as shared 
neurotransmitter systems.  Conversely, heterotypic sprouting involves pathways 
dissimilar to that of the injured pathway.  While injury-induced reorganization may lead 
to some restoration of function, changes in circuitry may also prove to be detrimental.  It 
has been proposed that the balance between compensatory and maladaptive sprouting 
may lie within the degree of homotypic compared to heterotypic sprouting (Ramirez, 
2001).  While homotypic sprouting is generally associated with functional recovery, 
consequences of heterotypic sprouting can range from beneficial to detrimental.  This 
relationship is further expanded by the principles of isomorphism, synergism, and 
dissonance (Steward, 1982, Sabel, 1999).  The principle of isomorphism states that the 
probability that sprouting will contribute to functional recovery increases as a function of 
the similarity between the compensating and injured pathways.  The principle of 
synergism suggests that probability that heterotypic sprouting will contribute to 
functional recovery increases as a function of the similarity between the outcome of 
sprouted afferent activity and that of the original, injured pathway.  As the inverse of 
synergism, the principle of dissonance proposes that the probability that heterotypic 
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sprouting will be detrimental increases as a function of the dissimilarity in the outcome of 
heterotypic afferent activity and that of the original, injured pathway.   
Lesion-induced sprouting can be observed throughout the hippocampus.  
Transection of the Schaffer collaterals both in hippocampal explant cultures as well as in 
vivo leads to an increase in the number and length of axon collaterals branching within 
CA3 and extending into CA1 (McKinney et al., 1997, Dinocourt et al., 2006, Aungst et 
al., 2013).  The increase in axonal sprouting and extension is spatially and temporally 
correlated with an increase in immunoreactivity for growth associated protein-43 (GAP-
43) within these regions.  Injury to the entorhinal cortex leads to a 20-30% widening of 
the commissural/associational (C/A) projections due to either expansion of C/A terminal 
field or extension of granule cell basal dendrites (Lynch et al., 1973, Storm-Mathisen, 
1974, Lynch et al., 1976, Goldowitz and Cotman, 1980, Laurberg and Zimmer, 1981, 
West, 1984.  Injuries leading to deafferentiation of dentate granule cells can induce 
sprouting of the mossy fiber projections {Laurberg, 1981 #47, Schauwecker and McNeill, 
1995, Styren et al., 1995).  In some cases, the sprouted mossy fibers have been observed 
to aberrantly synapse with dendrites of other granule cells, potentially creating a recurrent 
circuit (Frotscher and Zimmer, 1983).  These studies also demonstrated that mossy fiber 
sprouting can be induced by damage to the CA3 subregion.  Lesion-induced sprouting 
was first affiliated with epilepsy disorders by Messenheimer and Steward (Messenheimer 
et al., 1979).  Areas within the hippocampus that demonstrate high propensity for 
plasticity and structural reorganization are important for kindling.
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Mossy fiber sprouting in TLE 
Induction of TLE in rodent models typically leads to two distinct alterations to the 
mossy fiber pathway: sprouting of mossy fiber axon collaterals and the formation of basal 
dendrites on dentate granule cells (Nadler et al., 1980, Spigelman et al., 1998).  Mossy 
fiber sprouting is consistently observed following chemically-induced SE, reaching its 
peak approximately 2-3 months post-insult (Okazaki et al., 1995, Sutula et al., 1998, 
Wenzel et al., 2000, Lew and Buckmaster, 2011).  In human tissue samples, the degree of 
mossy fiber sprouting is thought to be dependent on the stage of TLE (Mathern et al., 
1995a, Mathern et al., 1995b).  Biocytin labeling of individual dentate granule cells 
confirmed that mossy fiber axons bifurcate within the hilus and aberrantly project into the 
inner molecular layer where they are likely to contact the dendrites of other granule cells.  
Electron microscopy has revealed that sprouted mossy fibers form a variety of new 
synapses, with a single mossy fiber forming an estimated 500 new synapses (Buckmaster 
et al., 2002).  Within the inner molecular layer of animal and human samples, synapses 
are formed between mossy fiber terminals and granule cell dendrites as well as inhibitory 
interneurons (Isokawa et al., 1993, Buckmaster et al., 2002, Frotscher et al., 2006).  
Quantitative analysis revealed that the majority of new synapses formed are asymmetric, 
with synapses between mossy fibers and inhibitory interneurons accounting for less than 
5% (Buckmaster et al., 2002, Cavazos et al., 2003).  It is unknown if what appears to be 
preferential synaptogenesis is truly selective or if it is simply opportunistic, given the loss 
of inhibitory interneurons in TLE.  Interestingly, while sprouted mossy fiber collaterals 
expand within the granule layer and the inner molecular layer, labeling of individual 
granule cells suggests they do not overlap with dendrites of the original granule cell 
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(Buckmaster et al., 2002).  Therefore, the presence of autapses within the recurrent circuit 
is unlikely (Koyama and Ikegaya, 2004).  While innervation of the inner molecular layer 
is the most prominent example of mossy fiber plasticity, collateral extension within the 
hilus, as well as, expansion of the terminal field within the CA3 subregion has been 
observed (Represa and Ben-Ari, 1992, Sutula et al., 1998, Buckmaster and Dudek, 1999, 
Holmes et al., 1999).  Additionally, TLE-induced plasticity is not limited to mossy fiber 
axons.  Sprouting and extension has also been observed in granule cell dendrites and 
within CA1 projections (Spigelman et al., 1998, Buckmaster and Dudek, 1999, Esclapez 
et al., 1999, Ribak et al., 2000, Smith and Dudek, 2001).   
In models where TLE is initiated by SE, it was debated whether mossy fiber 
sprouting was a consequence of the macroscopic damage induced by SE or of the 
seizures elicited by sustained SE (Sutula, 2002).  The presence of mossy fiber sprouting 
in kindling models supports the hypothesis that seizure activity is important for structural 
reorganization in TLE.  Sprouting of mossy fiber collaterals into the inner molecular 
layer can be observed after only a few seizures and progresses with repeated stimulations 
(Cavazos et al., 1991).  Similar to the reorganization elicited following lesion or SE, 
mossy fiber sprouting in kindled animals is permanent.  In general, seizure-induced 
mossy fiber reorganization can be seen in genetic models of epilepsy, following repeated 
electroconvulsant seizures, and systemic administration of chemoconvulsant agents 
(Stanfield, 1989, Golarai et al., 1992, Qiao and Noebels, 1993, Holmes et al., 1998, 
Gombos et al., 1999, Holmes et al., 1999, Vaidya et al., 1999).  In hippocampal explant 
cultures, hyperexcitation by the GABAA receptor antagonist picrotoxin was sufficient to 
induce mossy fiber sprouting (Koyama et al., 2004).  This reorganization of hippocampal 
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circuits in response to seizure activity is not surprising.  Plasticity on the neuronal or 
whole circuit level has been observed following repeated activation of pathways within 
the limbic, brain stem, cortical, and subcortical regions of many species (Sutula, 2004).  
As circuit reorganization is observed as a direct result of injury or seizure activity, mossy 
fiber sprouting in TLE is likely attributed to a combination of the two factors.  It is 
logical to hypothesize that early phases of mossy fiber sprouting may be a direct result of 
injury-related mechanisms.  Additionally, as the initial injury is thought to lead to 
episodes of neuronal synchronization (Sutula, 2004), later phases of mossy fiber 
sprouting may be attributed to activity-dependent mechanisms associated with 
epileptiform activity.  Indeed, individual mossy fibers have been shown to exhibit 
activity-dependent plasticity (De Paola et al., 2003, Galimberti et al., 2006). 
Activity dependence 
Given the abnormal level of neuronal activity associated with seizures, it is not 
surprising that activity dependent processes have been implicated in epileptogenesis.  
Blocking neuronal activity with tetrodotoxin (TTX) prevents the development of 
hyperexcitability in a neocortical injury model of epileptogenesis (Graber and Prince, 
1999, Graber and Prince, 2004).  The induction and maintenance of epileptiform activity 
in hippocampal slice models were also observed to be activity-dependent (Karr and 
Rutecki, 2008).  Activity-dependent release of neurotrophic factors has also been 
observed in animal models of TLE (Aloyz et al., 1999).   
While many of the proposed contributing factors of TLE demonstrate some 
activity-dependence, of particular interest is synaptic plasticity and network 
reorganization.  Activity-dependent neurite outgrowth has long been attributed to focal 
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changes in intracellular calcium concentration (Cohan and Kater, 1986, Connor, 1986, 
Fields et al., 1990, Schilling et al., 1991).  The growth promoting aspect of activity is 
constrained within a small range of calcium concentrations, outside of which retraction 
and growth cone collapse can occur, suggesting the process is tightly regulated (Kater et 
al., 1988, Dubinsky et al., 1989, van Pelt et al., 1996).  Such regulation allows for a 
reciprocal relationship between outgrowth and network connectivity (Van Ooyen et al., 
1995). Mechanistic studies have suggested that the rise in intracellular calcium necessary 
to promote growth may be attributed to calcium influx through N-methyl-D-aspartate 
receptors, L-type voltage-gated calcium channels, or both (Kocsis et al., 1994, Wayman 
et al., 2006).  Regardless of the initial route of calcium entry, preventing its secondary 
mobilization from intracellular stores abolishes the growth promoting effects of 
depolarization-induced activity (Kocsis et al., 1994).  Other than strict calcium 
dependence, the specific mechanisms underlying activity-dependent outgrowth are 
relatively unknown.  Second messenger systems, especially those responsive to changes 
in intracellular calcium such as cAMP, have been suggested to play a role (Mattson et al., 
1988).  Additionally, inhibitors of transcription have also been used to suggest that 
transcription – most likely of growth promoting genes – may be an important step linking 
activity to cytoskeletal dynamics (Solem et al., 1995).  Additional studies also suggest the 
importance of kinase cascades (Solem et al., 1995, Wayman et al., 2006). 
Functional consequences  
The impact of mossy fiber sprouting on network activity is highly debated, and 
may depend on type and number of post-synaptic targets (Sutula, 2002).  Synapse 
formation between sprouted mossy fibers and granule cells dendrites should form 
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recurrent excitatory circuits, whereas synapses formed with inhibitory interneurons may 
enhance overall inhibition (Tauck and Nadler, 1985).  Therefore, mossy fiber sprouting 
could lead to two functionally distinct outcomes.  Enhanced inhibition may compensate 
for hippocampal hyperexcitability and work to suppress the propagation of epileptiform 
events (Sloviter, 1991, 1992, Buhl et al., 1996, Kotti et al., 1997).  However, the percent 
increase in the number of synapses with inhibitory interneurons in TLE is only 16%, 
compared to the near 475% increase in synapses formed on granule cell dendrites 
(Claiborne et al., 1986, Acsady et al., 1998, Buckmaster et al., 2002).  Therefore, the 
novel formation of recurrent excitatory circuits may have more functional significance.  
The functional contribution of mossy fiber sprouting is further confounded by the finding 
that seizure activity increases the expression of GABA and its synthesizing enzyme 
glutamic acid decarboxylase-67 (GAD-67) within mossy fiber terminals (Gutierrez and 
Heinemann, 2001, Ramirez and Gutierrez, 2001, Gomez-Lira et al., 2002, Gutierrez, 
2002).  However, mossy fibers have also been shown to release zinc under these 
circumstances, which leads to inhibition of GABA receptors (Buhl et al., 1996, Coulter et 
al., 1996, Shumate et al., 1998).  Therefore, the significance of GABA transmission at 
sprouted mossy fiber terminals is still debated.  Some evidence from TLE patient samples 
supports the hypothesis that mossy fiber reorganization contributes to hippocampal 
hyperexcitability and, to some extent, epileptogenesis.  Correlations have been made 
between surgical removal of sprouting-prone hippocampal regions and decreases in 
seizure activity in human patients (Sutula et al., 1989), yet this evidence is circumstantial 
at best.  More convincingly, electrophysiological recordings of resected tissue revealed 
hyperexcitable responses of dentate granule cells following perforant path or mossy fiber 
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stimulation (Masukawa et al., 1989).  Additional correlations have been drawn between 
the extent of mossy fiber sprouting and abnormal antidromic field responses in a subset 
of TLE patients (Masukawa et al., 1992).   
Animal models of TLE induced by SE, kindling, or injury have allowed for more 
in-depth investigation of the consequences of mossy fiber sprouting on hippocampal 
networks.  Similar to studies of human tissue, loose correlations have been drawn 
between the duration and complexity of evoked multispike field potentials and the extent 
of mossy fiber sprouting in rodents (Tauck and Nadler, 1985).  Additionally, granule cell 
hyperexcitability following hilar stimulation is temporally correlated with mossy fiber 
sprouting (Wuarin and Dudek, 1996), and single stimulation of the perforant path led to 
an increased number of population spikes, followed by prolonged field sinks 
accompanied by irregular population spikes indicative of epileptiform activity (Patrylo et 
al., 1999).  Therefore, input from the entorhinal cortex may potentially be converted into 
epileptiform activity within the mossy fiber pathways (Koyama and Ikegaya, 2004).  
Inward current sinks have been observed within the inner molecular layer of fully but not 
partially kindled rats, spatially corresponding to the terminal field of sprouted mossy 
fibers (Golarai and Sutula, 1996).  This finding suggests that novel synapses formed 
between sprouted mossy fibers and granule cell dendrites are likely functional, which is 
essential to the hypothesis that mossy fiber sprouting leads to the formation of recurrent 
excitatory circuits.  Interestingly, many studies reveal increased local circuit excitation 
and epileptiform activity via increases in evoked and spontaneous EPSCs as well as 
spontaneous burst discharges that are only visible under conditions of decreased 
inhibition (Cronin et al., 1992, Patrylo and Dudek, 1998, Molnar and Nadler, 1999, 
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Okazaki et al., 1999, Patrylo et al., 1999, Lynch and Sutula, 2000, Wuarin and Dudek, 
2001).  It has also been suggested that during baseline activity levels, recurrent excitatory 
networks are functionally silent.  However, following high frequency stimulation, granule 
cells have been shown to synchronize (Feng et al., 2003).  Neuronal synchronization is 
thought to underlie much of the epileptic process.  The synchronization of granule cells is 
only observed in the presence of mossy fiber sprouting, thereby, connecting this 
structural reorganization with the most basic epileptic phenomenon.   
More direct evidence for the existence of recurrent excitatory circuits in TLE 
comes from elegant studies involving focal application of glutamate via microdrops or 
photolysis of caged glutamate.  Granule cell EPSPs were evoked following focal 
application of glutamate within the granule and inner molecular layer at long and variable 
latencies from the recorded cell (Wuarin et al., 1992, Wuarin and Dudek, 2001).  
Unfortunately, these studies do not allow one to definitively conclude that granule cells 
are monosynaptically connected.  However, using the dual patch clamp technique, 
Scharfman and colleagues demonstrated the formation of mutual synaptic connections 
among granule cells following seizure-induced mossy fiber sprouting (Scharfman et al., 
2003).  Given the multitude of potentially maladaptive changes occurring duing TLE, the 
question still remains if the development of recurrent excitation within the hippocampus 
can be solely attributed to structural reorganization.  Results from lesion-based studies 
suggest that injury-induced sprouting and reorganization is sufficient to cause 
hyperexcitability and, in some cases, epileptiform activity.  Transection of the Schaffer 
collaterals in hippocampal explant cultures led to an increase in the frequency of 
spontaneous EPSPs that correlated with increased axon sprouting and growth of CA3 
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pyramidal cells (McKinney et al., 1997, Aungst et al., 2013).  Stimulus-pair recordings in 
these cells demonstrated that the probability that any CA3 pyramidal cell was 
monosynaptically connected to another CA3 pyramidal cell was increased by 27% 
following injury.  Additionally, field stimulation of the CA3 subregion led to prominent 
polysynaptic depolarizing responses lasting over 500 ms in lesioned cultures.  This 
phenomenon was not attributed to decreased inhibition, suggesting the spread of 
excitation throughout the CA3 pyramidal cells was increased as a result of formation and 
extension of axon collaterals.  A small percentage of lesioned slices also exhibited 
classical epileptiform burst discharges.   
Despite evidence that mossy fiber sprouting can lead to the formation of recurrent 
excitatory circuits, there has been skepticism that it directly contributes to 
epileptogenesis.  Several studies have failed to detect a relationship between mossy fiber 
sprouting and the development or frequency of spontaneous recurring seizures in animal 
models (Longo and Mello, 1998, 1999, Pitkanen et al., 2000, Nissinen et al., 2001).  
Additionally, results gained from selective destruction of dentate granule cells by the 
neurotoxin colchicine during entorhinal kindling suggested that the dentate gyrus is not 
essential for hippocampal kindling (Dasheiff and McNamara, 1982, Frush et al., 1986, 
Sutula et al., 1986).  Prevailing theories supporting the importance of mossy fiber 
sprouting suggest that the formation of recurrent excitatory circuits by aberrantly 
sprouted mossy fibers may contribute to epileptogenesis under circumstances where other 
abnormalities, such as decreased inhibition, are also present (Sutula, 2002).  It has also 
been suggested that while mossy fiber sprouting may not be a direct cause of 
epileptogenesis, its presence may contribute to the chronic progression of TLE (Koyama 
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and Ikegaya, 2004).  In support of this hypothesis, the presence of mossy fiber sprouting 
seemed to increase the severity of spontaneous seizures (Zhang et al., 2002).  Kainate 
priming prior to the induction of SE in animal models of TLE, prevents mossy fiber 
sprouting without affecting the development of spontaneous recurrent seizures.  This 
finding is consistent with the hypothesis that mossy fiber sprouting is not involved in 
epileptogenesis.  However, the severity of spontaneous seizures was exacerbated in non-
primed animals with extensive mossy fiber sprouting compared to the primed animals 
that did not exhibit mossy fiber sprouting.  Therefore it was the conclusion of this study 
that the presence of mossy fiber sprouting may intensify the major symptoms of TLE.   
1.3. Mechanisms of mossy fiber sprouting 
Background 
As the mechanisms underlying mossy fiber sprouting are relatively unknown, few 
studies have been able to employ pharmacological strategies to target mossy fiber 
sprouting.  Therefore, it can be difficult to draw conclusions from the aforementioned 
studies that are more than strong correlations.  One strategy that has proven to be 
effective in altering mossy fiber sprouting in vivo is the inhibitor of mTOR signaling, 
rapamycin (Buckmaster et al., 2009).    The mammalian target of rapamycin (mTOR), a 
serine/threonine protein kinase, participates in a multitude of intracellular signaling 
cascades involved in neuronal processes such as differentiation, synaptic plasticity, ion 
channel expression, axonal growth, dendritic arborization, and survival (Tang et al., 
2002, Jaworski et al., 2005, Wullschleger et al., 2006, Abe et al., 2010, Wong, 2010, 
Galanopoulou et al., 2012).  Unfortunately, the results of these studies appear to be in 
contradiction with one another.  It was first demonstrated that administration of 6 mg/kg 
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rapamycin given to mice every other day following pilocarpine-induced SE reduced both 
mossy fiber sprouting and the frequency of spontaneous seizures (Zeng et al., 2009).  
However, when a lower dose of 3 mg/kg of rapapmycin was given to rats every day 
following kainic acid-induced SE, mossy fiber sprouting was again reduced yet the 
frequency of spontaneous seizures was not affected (Buckmaster and Lew, 2011).  In a 
distantly-related study, rats that had already developed spontaneous recurring seizures 
following pilocarpine-induced SE and treated with 5 mg/kg rapamycin every other day 
demonstrated reduced frequency of spontaneous seizures (Huang et al., 2010).  Another 
report details the effect of rapamycin on the electrophysiological correlates of epilepsy in 
hippocampal slices.  In this study, 6 mg/kg rapamycin was given daily for 6 days, starting 
24 hr following pilocarpine-induced SE.  After 6 days of treatment, rapamycin was then 
administered every other day for up to 2 months.  Mossy fiber sprouting was reduced 
following rapamycin treatment.  Single cell and field recordings from the dentate gyrus 
revealed that rapamycin prevented many electrophysiological alterations associated with 
TLE, including the repetitive firing of population spikes following antidromic stimulation 
(Tang et al., 2012).  Using a much higher dose of rapamycin, the Buckmaster group 
demonstrated that while mossy fiber sprouting was completely ablated by 10 mg/kg 
rapamycin given daily following pilocarpine-induced SE, the frequency of spontaneous 
seizures was not affected (Heng et al., 2013).  Up until this point, seizure frequency was 
determined by video observation and thereby limited to behavioral seizures alone.  
Recent work employs continuous video-EEG monitoring to detect spontaneous seizures 
in mice following TBI (Guo et al., 2013).  Along with preventing mossy fiber sprouting, 
daily administration of 6 mg/kg rapamycin after TBI reduced the percentage of animal 
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that developed spontaneous recurring seizures by ~37%.  Of the animals that did develop 
seizures, rapamycin treatment was associated with a reduction in seizure frequency.   
 It is possible that the contradicting results presented in these studies are attributed 
to differences in the TLE model, methods of outcome measurement, dosage/regimen, or 
species used.  However, as rapamycin is involved in a myriad of normal and pathological 
processes, its manipulation may be too broad to allow for conclusions to be drawn 
between two specific phenomena.  Therefore, a selective method for targeting mossy 
fiber sprouting is essential in order to definitively conclude that it is contributing to 
epileptogenesis.  The development of such a tool requires the understanding of molecular 
mechanisms underlying mossy fiber sprouting.  One theory proposes that the events 
following injury that lead to mossy fiber sprouting and reorganization may mirror those 
during development.  Mossy fiber guidance during development involves two distinct 
processes (Koyama et al., 2002).  Initially, mossy fibers are guided by the presence of 
chemoattractants from the CA3 region as well as chemorepellants from the CA1 region.  
There is also evidence of chemorepellants from the entorhinal cortex that prevent mossy 
fibers from innervating the granule and inner molecular layers (Holtmaat et al., 2003).  
Mossy fibers are then thought to use contact guidance cues, allowing them to fasciculate 
with other mossy fibers.  Aberrant sprouting of mossy fibers in TLE is also viewed as a 
two-step process (Koyama and Ikegaya, 2004).  The first step is the initial branching of 
collaterals within the hilus.  The second step involves extension of the sprouted 
collaterals and backward guidance into the inner molecular layer.  It is unknown if 
separate mechanisms are responsible for these processes.  In terms of guidance into the 
inner molecular layer, there is some evidence that the chemorepulsive cue that normally 
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prevents mossy fiber innervation in that region is lost in models of TLE (Holtmaat et al., 
2003).  Stellate cells projecting to the dentate gyrus from the entorhinal cortex provide a 
gradient of the chemorepellant Sema3A within the inner molecular layer, which is 
downregulated following status epilepticus.  Since contact guidance is typically bi-
directional, in the absence of the chemorepulsive cues from the entorhinal cortex, mossy 
fibers are free to enter the inner molecular layer.  The question remains as to what 
initiates the sprouting of mossy fiber collaterals?  One possibility is that sprouting is 
triggered by the release of extracellular signaling molecules either in response to the 
initial insult or seizure activity itself.  To identify which signaling molecules may be 
involved, the following criteria must be satisfied: production and release of the molecule 
is regulated by injury or seizure activity and its release must induce structural and 
functional changes that, in turn, result in hyperexcitability (He et al., 2002).   
BDNF 
Interestingly, mRNA levels of the neurotrophin brain-derived neurotrophic factor 
(BDNF) are elevated in the hippocampus, and more specifically, in dentate granule cells 
of TLE patients (Mathern et al., 1997).  BDNF activates tropomycin-related kinase 
receptors (Trks), initiating phosphorylation cascades involved in differentiation, cell 
survival, and synaptic plasticity (Kaplan and Miller, 2000).  Pyramidal cells within the 
hippocampus express high levels of TrkB receptors (Huang and Reichardt, 2001).  
Importantly, cultured dentate granule cells display functional TrkB activity and 
application of BDNF leads to axon branching (Patel and McNamara, 1995, Lowenstein 
and Arsenault, 1996a, b).  Increased levels of BDNF expression and corresponding 
activation of the TrkB receptor are observed within granule cell somas and mossy fiber 
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axons following insults often association with TLE, such as TBI, status epilepticus, and 
transient global ischemia (Yang et al., 1996, Hu et al., 1999, Oyesiku et al., 1999, Grundy 
et al., 2000, Hu et al., 2000, Griesbach et al., 2002, Hu et al., 2004, Heinrich et al., 2011).  
Other evidence suggests that seizure activity alone may be sufficient to induce increased 
BDNF expression and activation of TrkB.  Limbic seizures lead to increased levels of 
BDNF mRNA and protein within the dentate gyrus in vivo which appeared to peak 24-48 
hours following induction (Isackson et al., 1991, Nawa et al., 1995, Yan et al., 1997, 
Elmer et al., 1998, Vezzani et al., 1999, Katoh-Semba et al., 2001).  Along these lines, 
increases in BDNF expression and activation of TrkB are observed during kindling 
(Binder et al., 1999a, He et al., 2002).  As previously mentioned, hyperexcitation of 
hippocampal explant cultures can lead to mossy fiber sprouting.  Interestinglu, regions 
corresponding to the mossy fiber sprouting also demonstrate elevated levels of BDNF in 
these slices (Koyama et al., 2004).  Increased BDNF and TrkB activation are also 
observed to correspond to regions of GAP43 expression following Schaffer collateral 
transection in explant cultures (Dinocourt et al., 2006, Aungst et al., 2013).  These studies 
provide evidence that increases in BDNF expression and subsequent activation of the 
TrkB receptor correspond temporally and spatially with injury and seizure-induced 
sprouting.  However, mossy fiber sprouting and hyperexcitability must be directly linked 
with BDNF in order for it be considered as a potential candidate.   
 Application of BDNF on cultured dentate granule cells causes a concentration 
dependent increase in axon branching which is prevented by blockade of the TrkB 
receptor (Koyama et al., 2004).  Similarly, chronic activation of TrkB receptors leads to 
increased axonal sprouting and excitability within hippocampal slice cultures (Schwyzer 
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et al., 2002).  Interestingly, chronic infusion of BDNF into the rodent hippocampus is 
sufficient to lead to motor seizures and increased sensitivity to the pro-convulsant 
pilocarpine (Scharfman et al., 2002).  Similar results were observed in transgenic mice 
overexpressing BDNF (Croll et al., 1999).  Additionally, increased TrkB activity is 
associated with increased rate of epileptogenesis in mice (Heinrich et al., 2011).  
Conversely, decreased epileptiform spiking was observed following SE in transgenic 
mice overexpressing a truncated, dominant negative TrkB receptor (Lahteinen et al., 
2002). Intraventricular infusion of antibodies against the TrkB, but not TrkA or TrkC 
receptors, decreased epileptogenesis during kindling, once again confirming the 
specificity of this phenomenon (Binder et al., 1999b).  While kindling was only 
marginally impaired in BDNF +/- and BDNF -/- mice, conditional deletion of the TrkB 
receptor completely prevented its development (Kokaia et al., 1995, He et al., 2004).  
These findings provide a clear link between TrkB signaling and epileptogenesis.  Insight 
from hippocampal slice cultures may illuminate BDNF/TrkB’s involvement in mossy 
fiber sprouting and how it may contribute to epileptogenesis.  Decreased TrkB activity, 
either via knockdown or small molecule inhibition, prevents sprouting or impairs the 
development of hyperexcitability following Schaffer collateral transection (Dinocourt et 
al., 2006, Aungst et al., 2013).  The most convincing evidence for a direct link between 
BNDF signaling, mossy fiber spouting, and the development of hyperexcitability comes 
from the work of Koyama and colleagues.  BDNF-containing beads placed in the hilus of 
hippocampal slice cultures were sufficient to induce mossy fiber sprouting and aberrant 
innervation of the inner molecular layer which was blocked by TrkB inhibition (Koyama 
et al., 2004).  Hilar microstimulation in BDNF bead-containing but not control slices 
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elicited paroxysmal depolarization shifts reminiscent of interictal spikes typically 
recorded by electroencephalogram.  These depolarization shifts, considered as the basis 
for epileptiform activity, are typified by sustained elevation of the resting potential above 
normal threshold levels, accompanied by action potential bursts (Ayala et al., 1973, 
Dichter and Ayala, 1987).  Therefore, exogenous BDNF is sufficient to induce mossy 
fiber sprouting which led to the formation of recurrent excitatory circuits in hippocampal 
slices.   
GSK3β 
 Downstream of TrkB activation, phosphoinositide 3 kinase (PI3K) intitiates the 
phosphorylation and activation of protein kinase B, also known as Akt (Alessi et al., 
1996, Bhave et al., 1999).  Evidence of increased Akt activation within the hippocampus, 
as well as other regions, has been observed following many insults that often predispose 
for TLE, such as TBI (Zhang et al., 2006, Zhao et al., 2012), hypoxia-ischemia (Ouyang 
et al., 1999, Namura et al., 2000, Janelidze et al., 2001, Noshita et al., 2001, Yano et al., 
2001, Endo et al., 2006, Li et al., 2008, Xiong et al., 2012), and SE ( (Lopes et al., 2012).  
Interestingly, Akt is also involved in mTOR signaling (Wu and Hu, 2010).  That 
rapamycin reduces mossy fiber sprouting provides further support for the involvement of 
Akt and its substrates in this process.  Upon activation, Akt phosphorylates and 
inactivates glycogen synthase kinase 3 beta (GSK3β) (Cross et al., 1995).  Corresponding 
to changes in Akt activity, levels of phosphorylated (inactive) GSK3β are increased 
following TBI (Shapira et al., 2007, Dash et al., 2011, Zhao et al., 2012), hypoxia-
ischemia (Sasaki et al., 2001, Endo et al., 2006, Xiong et al., 2012), and SE (Lee et al., 
2012).  Intriguingly, preventing GSK3β inactivation following the induction of SE, also 
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reduced mossy fiber sprouting (Lee et al., 2012).   This result suggests that inactivation of 
GSK3β may be a crucial step along the TrkB signaling cascade responsible for mediating 
mossy fiber sprouting.   
 Originally identified for its role in glycogen metabolism, it is now known that the 
tonically active kinase aids in the regulation of a variety of neuronal functions.  For 
example, phosphorylation by GSK3β regulates the activity of transcription factors 
involved in cell proliferation and growth, synaptic plasticity, and cell death (Boyle et al., 
1991, Struthers et al., 1991, Wang et al., 1994, Davis et al., 1996, Karin et al., 1997, Silva 
et al., 1998, Bevilaqua et al., 1999, Shaywitz and Greenberg, 1999).  GSK3β is also well 
known for its role in cytoskeletal dynamics via regulation microtubule associated proteins 
such as tau, MAP1B, MAP2, NCAM, and neurofilament proteins, whose function is 
determined by phosphorylation state (Mackie et al., 1989, Guan et al., 1991, Hanger et 
al., 1992, Mandelkow et al., 1992, Berling et al., 1994, Guidato et al., 1996, Sánchez et 
al., 1996, García-Pérez et al., 1998, Lucas et al., 1998).  One particular substrate that may 
be of  importance in microtubule dynamics is the intracellular phosphoprotein collapsin 
response mediator protein 2 (CRMP2) (Figure 1.2).   
1.4. Collapsin Response Mediator Protein 2 (CRMP2) 
Background 
CRMP2, also known as DPYSL2/DRP2, Unc-33, Ulip, or TUC2, was first 
identified as a mediator of axon growth and guidance in chick dorsal root ganglia 
(Goshima et al., 1995), with analogs later identified in Caenorhabditis elegans, 
Drosophila melongaster, rodents, and humans (Hedgecock et al., 1985, Geschwind and 
Hockfield, 1989, Minturn et al., 1995, Byk et al., 1996, Kitamura et al., 1999, Morris et  
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Figure 1.2.  Signaling cascade potentially involved in mossy fiber sprouting.  
Activation of the growth factor receptor TrkB by the binding of BDNF leads to the 
activation of Akt through the depicted pathway.  Akt inactivates GSK3β, thereby 
increasing the amount of active CRMP2 available to promote neurite outgrowth. 
(BDNF: brain-derived neurotrophic factor; TrkB: tropomycin-related kinase receptor  
B; PI3K: phosphoinositide 3-kinase; PIP3: phopshotidylinositol (3,4,5)-trisphosphate; 
PDK1: phosphoinositide-dependent kinase; Akt: protein kinase B; GSK3β: glycogen 
synthase kinase 3β; CRMP2: collapsin response mediator protein 2) 
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al., 2012).  CRMP2 is widely expressed within both the central and peripheral nervous 
systems (Goshima et al., 1995), as well as in fibroblasts and T cells (Vincent et al., 2005, 
Vuaillat et al., 2008).  Five structurally similar proteins (CRMP1-5) comprise the 
mammalian CRMP family, with CRMP2 being the most well-studied (Fukada et al., 
2000, Schmidt and Strittmatter, 2007).  Resolution of the CRMP2 structure revealed a 
“bilobed-lung” configuration that is believed to be shared by all CRMPs as it was also 
observed following crystallization of CRMP1 (Deo et al., 2004, Stenmark et al., 2007).  
Intriguingly, CRMP family members are known to form hetero- and homotetramers, with 
the latter being less likely as many CRMP protein demonstrate lower affinity for itself 
compared to other family members (Wang and Strittmatter, 1997, Yoneda et al., 2012).  
While the presumed native configuration for CRMPs is tetrameric, the impact of 
oligomerization on CRMP function is unknown and likely depends on the composition of 
the tetramer.  As CRMP2 is the most widely expressed of all family members (Wang and 
Strittmatter, 1996), many tetramers likely contain at least one CRMP2 monomer.  
Canonical functions of CRMP2 include axonogenesis, neurite outgrowth, migration, and 
neuronal polarity (Inagaki et al., 2001, Nishimura et al., 2003, Yoshimura et al., 2005).  It 
is now known that CRMP2 also participates, mainly through trafficking, in protein 
endocytosis and vesicle recycling, synaptic assembly, calcium channel regulation, and 
neurotransmitter release (Hensley et al., 2011, Khanna et al., 2012).  Many of these 
functions require an interaction between CRMP2 and multiple binding partners.  For 
example, CRMP2’s involvement in cytoskeletal dynamics requires interactions with 
proteins such as tubulin, actin, and vimentin (Fukata et al., 2002, Vincent et al., 2005, 
Vuaillat et al., 2008).  Interactions with the motor proteins kinesin and dynein suggest 
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that CRMP2 may play an important role in trafficking, linking these proteins to their 
cargo packets (Nishimura et al., 2003, Kawano et al., 2005, Kimura et al., 2005, Lykissas 
et al., 2007, Arimura et al., 2009, Rahajeng et al., 2010).  Through interactions with both 
voltage- and ligand-gated calcium channels, CRMP2 is involved in synapse dynamics 
both pre- and post-synaptically (Al-Hallaq et al., 2007, Brittain et al., 2009, Chi et al., 
2009, Brittain et al., 2012).  Many other interactions have been observed whose 
functional impact are not well understood, such as the Ras-GAP Neurofibromin and the 
calcium sensing protein, calmodulin (Xu et al., 1990, Zhang et al., 2009).   
Post-translational regulation 
Along with o-glycosylation, sumoylation, and proteolysis, CRMP2 is 
phosphorylated by numerous kinases (Arimura et al., 2000, Brown et al., 2004, Cole et 
al., 2004, Arimura et al., 2005, Yoshimura et al., 2005, Cole et al., 2006, Lykissas et al., 
2007, Hou et al., 2009, Uchida et al., 2009, Varrin-Doyer et al., 2009).  As knowledge 
progresses, it appears that many of CRMP2’s functions are regulated by phosphorylation, 
especially its canonical functions.  CRMP2 promotes neurite outgrowth by two distinct 
mechanisms: (1) binding and transporting tubulin dimers from the soma to distal 
projections (Fukata et al., 2002, Kimura et al., 2005) and (2) stabilizing the growing end 
of the microtubule by promoting the inherent GTPase activity of tubulin (Chae et al., 
2009).  Phosphorylation by GSK3β, cyclin dependent kinase 5 (CDK5), Rho-associated 
protein kinase (ROCK), calcium/calmodulin-dependent protein kinase II(CaMKII), or the 
tyrosine protein kinase, FYN, renders CRMP2 inactive, promoting neurite retraction and 
growth cone collapse (Arimura et al., 2000, Brown et al., 2004, Cole et al., 2004, 
Arimura et al., 2005, Uchida et al., 2005, Yoshimura et al., 2005, Cole et al., 2006, Hou 
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et al., 2009, Uchida et al., 2009).  Specifically, GSK3β phosphorylates CRMP2 at 
threonines 509, 514, and 518, thereby reducing its affinity for tubulin (Yoshimura et al., 
2005).  As there is no strict consensus motif, GSK3β substrate recognition can be 
complex, often requiring prior phosphorylation (priming) at a serine slightly c-terminal to 
the GSK3β site(s) (DePaoli-Roach, 1984, Fiol et al., 1988).  This type of hierarchical 
phosphorylation allows for complex regulation at multiple levels.  In the case of CRMP2, 
it must be first be phosphorylated at serine 522 by the serine/threonine kinase CDK5 in 
order to be phosphorylated by GSK3β (Yoshimura et al., 2005, Cole et al., 2006).  
Sequential phosphorylation of CRMP2 by CDK5 and GSK3β has been demonstrated for 
many facets of CRMP2 function, most importantly, neurite outgrowth (Brown et al., 
2004, Uchida et al., 2005).   Elegant studies by the Ohshima and Goshima groups suggest 
that changes in the phosphorylation state of CRMP2 may allow for dynamic regulation of 
outgrowth and branching patterns, as phosphorylation by CDK5 is necessary for proper 
bifurcation of CA1 apical dendrites as well as organization of dendritic fields (Yamashita 
et al., 2012, Niisato et al., 2013).  As phosphorylation at S522, T509, T514, and/or T518 
renders CRMP2 unable to promote neurite outgrowth, dephosphorylation of those 
residues should activate CRMP2, thereby increasing neurite outgrowth.  Indeed 
dephopshorylation of GSK3β sites by either protein phosphatases 1 (PP1) and 2A (PP2A) 
enhance neurite outgrowth in vitro (Cole et al., 2008, Zhu et al., 2010, Astle et al., 2011).   
Potential involvement in TLE 
The inactivation of GSK3β that is observed following TBI, SE, and hypoxia-
ischemia may lead to an overall decrease in the level of phosphorylated (inactive) 
CRMP2, thereby promoting neurite outgrowth.  Therefore, the structural reorganization 
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that is seen in these models and often associated with TLE, may potentially be attributed 
to increased CRMP2 activity.  Indeed, hypophopshorylation of CRMP2 has been 
observed following hypoxia-ischemia (Zhou et al., 2008, Sato et al., 2011), validating 
CRMP2 as the potential link connecting inactivation of GSK3β to insult induced 
structural plasticity.  However, the multifunctional nature of CRMP2 provides a complex 
hurdle in determining its contribution to specific phenomena.  The roles of CRMP2 
within the nervous system are as varied as they are numerous (Khanna et al., 2012).  
Therefore, broad manipulations such as genetic knockdown are unlikely to yield valid 
information on specific CRMP2-dependent processes.  The ability to selectively target 
the capacity of CRMP2 to promote neurite outgrowth is necessary in order to definitively 
determine the involvement of CRMP2 in TLE.   
1.5. (R) Lacosamide 
Background 
It has been suggested that a novel antiepileptic drug, Lacosamide (Vimpat®) (R-
N-benzyl 2-acetamido-3-methoxypropionamide) ((R)-LCM) binds and impairs the ability 
of CRMP2 to promote neurite outgrowth; however, this is somewhat controversial.  (R)-
LCM is a first in class AED approved by the United States Food and Drug 
Administration and the European Medicines Agency for adjunctive treatment of partial-
onset epilepsy with or without secondary generalization in adults (for review see (Biton, 
2012)).  (R)-LCM was first identified as the lead compound in a class of functionalized 
amino acids demonstrating antiepileptic properties in the maximal electroshock model 
(Cortes et al., 1985, Choi et al., 1996). 
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Mechanism of action 
Despite its success in both pre-clinical and clinical studies, the mechanism by 
which (R)-LCM alleviated seizure activity remained unknown (Duncan and Kohn, 2005).  
Radioligand displacement studies attempted to identify a target for (R)-LCM within the 
central nervous system.  While the ability of (R)-LCM to weakly displace H
3
-
Batrachotoxin indicated some level of binding to voltage-gated sodium channels 
(VGSCs), (R)-LCM treatment did not affect steady state gating kinetics or current density 
(Errington et al., 2006).  It was ultimately determined that (R)-LCM reduces excitability 
through selective enhancement of VGSC slow inactivation (Errington et al., 2008).  It 
was hypothesized that this unique method of action would allow for discrimination 
between steady-state and aberrantly increased levels of firing.  (R)-LCM derivatives were 
employed as affinity baits in an attempt to identify any additional targets within the 
central nervous system (Beyreuther et al., 2007, Park et al., 2009, Park et al., 2010).  The 
results of these studies suggested that, aside from the voltage-gated sodium channel, (R)-
LCM may also target CRMP2.   
Controversy 
The first evidence supporting the interaction can be found in the preclinical report 
published by Beyreuther and colleagues on behalf of Shwarz Biosciences (Beyreuther et 
al., 2007).  Direct evidence supporting their claims that CRMP2 is a target of (R)-LCM 
can be found within a patent application filed by three of the authors: Beyreuther, Stohr, 
and Freitag (Beyreuther et al., 2009).  The most convincing data within the application 
are the radioligand binding studies where they demonstrated competitive and specific 
binding of [
14
C]-(R)-LCM to crude fractions isolated from Xenopus Oocytes transfected 
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with CRMP2, as well as rat brain membranes.  These studies reported a Kd-value lower 
than 5 µM.  Importantly, radioligand binding could be competed off with an excess of 
cold, unlabeled (R)-LCM.  Additionally, no specific binding was reported from control 
Oocyte fractions not containing CRMP2.  Based on these results, along with others 
supporting the interaction of CRMP2 and (R)-LCM, the application states the following: 
“CRMP2 is therefore regarded as a target of (R)-LCM in the nervous system in epilepsy, 
pain, essential tremor, dyskinesias, amyotrophic lateral sclerosis, schizophrenia, and other 
disease conditions” (Beyreuther et al., 2009). Affinity-bait capture of CRMP2 by (R)-
LCM has been demonstrated in three separate reports (Park et al., 2009, Park et al., 2010, 
Wang et al., 2010a).  Furthermore, in silico docking was used to identify putative binding 
sites for (R)-LCM within the CRMP2 protein.  The technique uses the known structure of 
the target protein (CRMP2) to predict the structure of the intermolecular complex when 
bound to a ligand ((R)-LCM) (for review see (Sousa et al., 2006)).  A total of 100 runs 
were carried out over the surface of the CRMP2 protein to yield five pockets capable of 
coordinating (R)-LCM binding.  Interestingly, it was observed that CRMP2 expression 
levels can influence the ability of (R)-LCM to transition voltage-gated sodium channels 
to the slow-inactivated state in a neuronal cell line.  Site-directed mutagenesis of key 
residues within the previously identified binding pockets on CRMP2 prevented the 
impact of CRMP2-overexpression on modulation of VGSC slow inactivation by (R)-
LCM.  
Evidence for a direct interaction between (R)-LCM and CRMP2 was disputed in a 
2012 report by Wolff and colleagues (Wolff et al., 2012).  Previous radioligand binding 
studies reported a Kd of ~5µM; however these employed [
14
C] (R)-LCM which was 
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reported to have low specific radioactivity, limiting further binding studies.  Therefore, 
Wolff and colleagues used [
3
H] (R)-LCM, whose specific activity was 1000 fold higher 
than that of [
14
C] (R)-LCM.  No specific binding was observed in fractions taken from rat 
cortex, hippocampus, striatum, or cerebellum that were incubated with 300 nM [
3
H] (R)-
LCM.  To maximize CRMP2 levels, fractions were taken from CRMP2-expressing 
oocytes and incubated with 969 nM [
3
H] (R)-LCM.  Still, no specific binding was 
observed.  CRMP2 expressed in Cos-7 cells was sequestered by coupling to SPA beads 
prior to incubation with 600 nM [
3
H] (R)-LCM.  Again, no specific binding was reported.  
Surface plasmon resonance studies revealed no detectable interaction between 
immobilized CRMP2 and (R)-LCM, ranging in concentration from 0.39-100 µM.  Based 
on the lack of specific binding in this report, the authors infer that any effects of (R)-
LCM on CRMP2, or vice versa, must be indirect in nature.  The authors suggest that 
results gleaned from affinity bait studies do not provide direct evidence that CRMP2 is a 
target of (R)-LCM.  As the structure of the ligand required modification (addition of 
Affinity Bait and Chemical Rreporter moieties), the observed interaction may be a result 
of an altered receptor interaction profile.  Additionally, the authors refute the existence of 
(R)-LCM binding pockets, identified by in silico docking, within the CRMP2 protein.  
They report, based on personal communication with a colleague, the co-crystallization of 
CRMP2 in the presence of (R)-LCM did not reveal a specific binding site.  While 
evidence suggests that CRMP2 may be a target of (R)-LCM, it was unclear if this 
interaction would impact the function of CRMP2.  If (R)-LCM were able to selectively 
target CRMP2-mediated neurite outgrowth, it would be an extremely valuable tool in 
understanding the contribution of CRMP2 in mossy fiber sprouting.  
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Impact on epileptogenesis 
As epileptogenesis is thought to involve changes in neuronal excitability, as well 
as, network reorganization, the ability of (R)-LCM to potentially target not only activity, 
but also structural plasticity may afford efficacy in the prevention of epileptogenesis, 
where so many classical antiepileptics have failed.  However, the anti-epileptogenic 
potential of (R)-LCM relies heavily on the assumption that the relationship between 
aberrant sprouting and epileptogenesis is causal in nature.  As the majority of AEDs are 
not disease-modifying, they do not alter kindling acquisition.  However, work by Brandt 
and colleagues demonstrated that (R)-LCM treatment could hinder the progression of 
kindling (Brandt et al., 2006).  Rats were kindled by once-daily stimulation of the 
amygdala 0.5 hrs following intra-peritoneal injection of 3, 10, or 30 mg/kg (R)-LCM.  
Both the severity of seizures and duration of after-discharges elicited by each current 
injection were decreased in animals treated with 10 or 30 mg/kg (R)-LCM.  Additionally, 
(R)-LCM treatment led to a ~90% increase in the number of stimulations required for 
kindling.  In fact, while all of the vehicle-treated rats were successfully kindled, only 8/10 
and 7/10 rats reached kindled status in the 10 and 30 mg/kg treatment groups, 
respectively.  To determine if the effect of (R)-LCM was long-lasting, after 22-23 days of 
stimulation rats were allowed a 2.5 month washout period, during which they received no 
current injections.  All rats were able to be rekindled within 4 stimulations, regardless of 
prior (R)-LCM treatment.  This outcome can be explained in a variety of ways.  Of the 
rats used for the washout experiments, 7/10 (R)-LCM treated rats and 10/10 vehicle 
treated rats had reached kindled status, which by definition insinuates that all rats 
underwent class V seizures in response to the same current injection.  Therefore, as the 
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seizure severity was relatively conserved across treatment groups, differences following a 
treatment-free washout period were unlikely.  For this reason, previous work involving 
washout periods following amygdala stimulations excluded animals which had reached 
kindled status prior to washout (Loscher et al., 1998).  In these studies, which identified 
potential anti-epileptogenic properties of the AED levetiracitam, the rate of kindling 
following washout was slower in previously exposed animals.  Once kindling was 
obtained, however, focal seizure threshold was not different from controls.  Therefore it 
is possible that while the kindling model provides a framework for anti-epileptogenic 
intervention, once kindling status has been reached the opportunity for prophylaxis may 
have passed.  Alternatively, as (R)-LCM lowers excitability by enhancing sodium 
channel slow-inactivation, treatment directly prior to stimulation may have simply 
dampened the response to the current injections, thereby impeding the kindling process.   
 (R)-LCM treatment was associated with a dose-dependent decrease in the number 
of spontaneous recurrent seizures 6 weeks following induction of status epilepticus 
(Wasterlain et al., 2011).  As the development of spontaneous recurring seizures is 
dependent upon successful, sustained status epilepticus, it is possible that the reduction of 
seizures is a direct result of (R)-LCM interfering with the induction process.  Therefore, a 
second group of animals received (R)-LCM treatment 40 minutes following perforant 
path stimulation.  While all of the vehicle-treated animals demonstrated SRS, they were 
only observed in 3 of 9 (R)-LCM-treated animals.  Interestingly, of the animals that did 
develop SRS, there was no difference in the number of seizures across groups, suggesting 
that the development of SRS may be an all or nothing process.   That late (R)-LCM 
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treatment was able to prevent the development of SRS in 67% of animals suggests that 
(R)-LCM may have some anti-epileptogenic potential.   
The ability of (R)-LCM to alter injury-induced increases in connectivity was 
investigated using the undercut (neocortical isolation) model of posttraumatic 
epileptogenesis.  In this model, axon sprouting has been demonstrated by morphological 
reconstruction of axons of the layer V pyramidal neurons (Salin et al., 1995) and by 
functional mapping of excitatory synaptic connectivity using laser scanning 
photostimulation of caged glutamate (Jin et al., 2006).  Animals received daily (R)-LCM 
treatments for 1 week following surgery, upon which time the animals were allowed to 
for an additional week.  While field potential recordings did not reveal a difference in the 
frequency of evoked epileptiform events, the mean amplitude of the recordings was 
significantly lower in (R)-LCM treated animals.  Importantly, electrophysiological 
recordings from layer V pyramidal neurons revealed a decrease in the frequency of 
spontaneous excitatory post-synaptic currents.  A decrease in frequency without a change 
in the amplitude or kinetics (rise time, decay time, constant, and ½ width of events) is 
indicative of a decrease in the number of synaptic connections.  Indeed glutamate 
uncaging studies demonstrated a decrease in excitatory connectivity following (R)-LCM 
treatment (Figure 1.3).  As animals had undergone a 1-week washout period prior to all 
recordings, these results suggest that (R)-LCM may have had a disease-modifying effect 
following neocortical isolation.   
As previously mentioned, TBI is a common instigator of acquired epilepsy.  Mice 
receiving closed-head TBI were treated with (R)-LCM 30 minutes following injury and 
continuing twice daily for 3 days.  (R)-LCM treatment was associated with a decrease in  
39 
 
  
Figure 1.3.  (R)-LCM treatment reduces excitatory connectivity following neocortical 
isolation.  (A)  Timeline of experimental design.   Undercut surgery is represented as day 0.   
(R)-LCM or vehicle treatment began 1 day following surgery and continued for 7 days.   
Animals were allowed to recover from treatment until neocortical slices were obtained, 14-20 
days after surgery. (B) Average uncaging evoked EPSC maps of layer V pyramidal neuron in 
the undercut (UC) and UC + (R)-LCM groups. Arrowhead: soma; color scale: composite 
amplitude of evoked EPSCs (pA);black scale bar: 50 µm.  (C) Uncaging activated hotspots in 
average map of (R)-LCM treated-animals were significantly less than that of the injured 
control group.  (* < 0.05, Student’s t-test) (values represent mean ± SEM) (n = 16). From 
Wilson et al., Prevention of posttraumatic axon sprouting by blocking CRMP2-mediated 
neurite outgrowth and tubulin polymerization. Neuroscience. 2012. (Wilson et al., 2012) 
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neuronal injury that was correlated by a delay in the expression of pro-inflammatory 
mediator genes and reduced microglial activation (Wang et al., 2013).  (R)-LCM-treated 
mice demonstrated improved function in both the rotorod and Morris water maze 
paradigms.  Interestingly, the emergence of mossy fiber projections into the inner 
molecular layer was not altered by (R)-LCM treatment.  However, mossy fiber sprouting 
is viewed as a progressive process and is typically measured in much later stages 
following injury.  Unfortunately, the extent of mossy fiber sprouting was not examined at 
later time points.   
Recently, Licko and colleagues sought to expand previous reports on the anti-
epileptogenic potential of (R)-LCM (Licko et al., 2013).  To avoid any possible 
interference with the induction of sustained SE, (R)-LCM treatment began following its 
cessation and was continued for 23 days.  On the molecular level, many hallmarks 
associated with SE were altered by (R)-LCM treatment.  Chronic (R)-LCM treatment 
prevented both neurogenesis of granule neurons as well as cell loss within the piriform 
cortex and CA1 region of the hippocampus, yet did not impede the aberrant migration of 
neurons into the hilus.  Unfortunately, the extent of mossy fiber sprouting was not 
determined in this report.  However, (R)-LCM treatment was associated with a decrease 
in the number of SE-induced persistent basal dendrites present in the hilar region.  
Despite the impact on molecular changes induced by SE and contrary to previous reports, 
(R)-LCM treatment did not successfully prevent the development of spontaneous 
recurring seizures.  Additionally, latency to first seizure and the frequency of spontaneous 
seizures were not attenuated by chronic (R)-LCM treatment.  While the treatment 
paradigm was somewhat unorthodox, combining oral administration and continuous 
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infusion via osmotic minipump, it is unlikely that this would account for the lack of 
efficacy in preventing the development of spontaneous seizures.  In light of all the 
aforementioned work in vivo, it is difficult to determine whether (R)-LCM is anti-
epileptogenic in nature. 
1.6. Thesis aims 
 As the molecular mechanisms contributing to mossy fiber sprouting in acquired 
epilepsies are relatively unknown, in this thesis I will investigate the potential role of 
CRMP2 in this phenomena.  In order to do so, a tool must be developed for selectively 
targeting CRMP2 activity.  It is my hypothesis that the inactivation of GSK3β following 
the precipitating injury underlies an increase in CRMP2 activity which contributes to 
increased plasticity and circuit reorganization (i.e. mossy fiber sprouting).  To test this 
hypothesis I employed the following aims: 
1. In order to identify a method for preferentially targeting CRMP2-mediated neurite 
outgrowth, I propose to determine if CRMP2 function is directly impacted by 
interaction with (R)-LCM. 
2. To avoid the impact of (R)-LCM on voltage-gated sodium channels, I propose to 
identify a derivative of (R)-LCM that selectively targets CRMP2. 
3. As GSK3β is inactivated following TLE-related insults I propose to determine if 
CRMP2-mediated neurite outgrowth is regulated by changes in GSK3β activity. 
4. As injury results in inactivation of GSK3β, I propose to determine if CRMP2 
phosphorylation is altered following TBI. 
5. As many epileptogenic processes are attributed to activity-driven phenomena, I 
propose to determine if CRMP2 phosphorylation is regulated by neuronal activity. 
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6. As CRMP2 activity appears to be increased throughout the latent period following 
injury, I propose to determine if targeting CRMP2 in vivo prevents mossy fiber 
sprouting followingTBI. 
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CHAPTER 2. MATERIALS AND METHODS 
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2.1.  Lacosamide compounds and recombinant proteins 
(R)- and (S)-LCM, as well as, several other derivatives for in vitro studies were 
generously provided by the laboratory of Harold Kohn, Ph.D. at the University of North 
Carolina, Chapel Hill.  Additionally, (S)-LCM for in vivo studies was provided by the 
laboratory of Ki Duk Park, Ph.D. at the Korea Institute of Science and Technology.  
Recombinant CRMP2 and CRMP25ALA proteins were previously purified by a former 
member of the Khanna laboratory, Joel Brittain, Ph.D.  Briefly, a CRMP2-GST construct 
containing 5 amino acids in predicted LCM-binding regions of CRMP2 mutated to 
alanine (CRMP25ALAGST; Glu-360, Ser-363, Lys-418, Ile-420, and Pro-443) was 
generated by subcloning the mutation containing portion of CRMP25ALA into wild-type 
CRMP2-GST (using restriction enzymes RsrII and BglII).  Both wild-type and mutant 
recombinant proteins were purified as previously described (Brittain et al., 2009, Wang et 
al., 2010a). 
2.2. NT-647 labeling of CRMP2 proteins 
Recombinant CRMP2 and CRMP25ALA proteins underwent primary amine 
labeling using the Monolith
TM
 NT.115 RED-NHS protein labeling kit (NanoTemper) per 
the manufacturer’s instructions.  Protein concentration was adjusted to 2-20 µM using the 
provided labeling buffer.  The concentration of dye was adjusted to 2-3 fold the 
concentration of the protein.  Protein and dye were mixed in a 1:1 ratio (200 µl final) and 
incubated 30 m in the dark at room temperature (RT).  Supplied gravity-flow columns 
were washed and equilibrated with the provided buffers.  Labeling mixture was loaded 
onto the column and eluted using a HEPES buffer.  The purity of the sample was 
determined by measuring the ratio of protein to dye via spectroscopy.  Protein absorption 
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was measured at 280 nm and compared to dye absorption at 650 nm.  Labeling resulted in 
a 1:1 ratio of protein to dye.  Calibration curves were completed using the Monolith 
NT.115 instrument (NanoTemper) and compared to free dye to determine the optimum 
concentration of labeled-protein to be used. 
2.3. Microscale Thermophoresis (MST) binding analyses  
MST, the directed movement of molecules in optically generated microscopic 
temperature gradients, permits an immobilization-free fluorescence methodology for the 
analysis of interaction of biomolecules (Wienken et al., 2010, van den Bogaart et al., 
2012). This thermophoretic movement is determined by the entropy of the hydration shell 
around molecules. The microscopic temperature gradient is generated by an infrared 
laser. In a typical MST experiment, the concentration of the labeled molecule is kept 
constant while the concentration of the unlabeled interaction partner is varied. A constant 
concentration of NT647-labeled CRMP2 or CRMP25ALA (final labeled protein 
concentration of 500 nM) was incubated for 10 min at room temperature in the dark with 
ascending concentrations of (R)- or (S)-LCM in MST buffer (Table 2.1). Immediately 
afterward, 3–5 μl of the samples were loaded into standard glass capillaries (Monolith NT 
Capillaries, NanoTemper), and the thermophoresis analysis was performed on a 
NanoTemper Monolith NT.115 instrument (40% LED, 40% IR laser power). The MST 
curves were fitted with a Hill method using GraphPad Prism 5 software to obtain Kd 
values for binding between CRMP2 and LCM compounds.   
2.4. Primary cortical neuron cultures 
Rat cortical neuron cultures were prepared from cortices dissected from 
embryonic day 19 (E19) rats as described (Goslin and Banker, 1989), with some  
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Table 2.1. Buffers 
Buffer Contents 
Depolarizing 
Tyrode’s 
32 mM NaCl, 90 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 25 mM HEPES 
pH 7.5, 30 mM Glucose 
External Sodium 
Recording Solution 
100 mM NaCl, 10 mM tetraethylammonium chloride (TEA-Cl), 1 mM 
CaCl2, 1 mM CdCl2., 1 mM MgCl2, 10 mM D-glucose, 4 mM 4-AP, 0.1 
mM NiCl2, 10 mM HEPES (pH 7.3, 310-315 mOsm/L) 
G-PEM Buffer 80 mM PIPES, pH 6.9, 1 mM EGTA, 2 mM MgCl2, 5% Glycerol 
Glucose-Free BSS 
116 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO4, 1.0 mM NaH2PO4, 26.2 
mM NaHCO3, 0.8 mM CaCl2, 20 mM sucrose 
Internal Sodium 
Recording Solution 
110 mM CsCl, 5 mM MgSO4, 10 mM EGTA, 4 mM ATP Na, and 25 mM 
HEPES (pH 7.2, 290-310 mOsmo/L) 
MST Buffer 
20 mM Tris, 150 mM NaCl, 0.01 mM EDTA with 0.01% Polyoxyethylene 
Sorbitan Monolaurate (Tween-20) 
Non-Depolarizing 
Tyrode’s 
119 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 25 mM HEPES 
pH 7.5, 30 mM Glucose 
Phopshate Buffer 8.1 mM Na2HPO4, 1.9 mM NaH2PO4 
Sodium Sulfide 
Perfusate 
150 mM NaS2, 8.1 mM Na2HPO4, 1.9 mM NaH2PO4 
TBST 
25 mM Tris-Cl, pH 8.0, 125 mM NaCl, 0.1% to 2% Polyoxyethylene 
Sorbitan Monolaurate (Tween-20) 
TIMM Solution 
132 mM Citric Acid, 79.5 mM Sodium Citrate, 153.6 mM Hydroquinone, 
5 mM AgNO3, 30% Gum Arabic 
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modifications. Briefly, cortices were dissected out of E19 rats, and cells were dissociated 
enzymatically and mechanically (trituration through Pasteur pipette) in a Papain solution 
(12 U/ml; Worthington) containing Leibovitz’s L-15 medium (Invitrogen), 0.42 mg/ml 
cysteine (Sigma), 250 U/ml DNase 1 (type IV; Sigma), 25 mM NaHCO3, penicillin 
(50U/ml)/streptomycin (50 μg/ml), 1 mM sodium pyruvate, and 1 mg/ml glucose 
(Invitrogen). After dissociation, the cells were gently washed by sequential centrifugation 
in Neurobasal medium containing either 2 mg/ml or 20 mg/ml BSA and Pen/Strep, 
glucose, pyruvate, and DNase1 (as above) and then plated on poly-D-lysine-coated 
coverslips or 96-well plates at ~400 cells per mm
2
. Growth media (1 ml/well or 100 
µl/well for 12- and 96-well plates, respecitvely) consisted of Neurobasal medium 
continaing 2% NuSerum, 2% NS21 (Chen et al., 2008), supplemented with 
penicillin/streptomycin (100 U/ml; 50 μg/ml), 0.1 mM L-Glutamine and 0.4 mML-
glutamax (Invitrogen).  5-fluoro-2′-deoxyuridine (1.5 μg/mL) (Sigma) was added 48 h 
after plating to reduce the number of nonneuronal cells. After 4 d in culture and 2× each 
week thereon, half of the growth medium was replaced with medium without 5-fluoro-2’-
deoxyuridine.  Cultures were mixed yet consisted predominantly of excitatory neurons 
(Figure 2.1). 
 Cortical neurons were chosen for the in vitro experiments despite the apparent 
disconnect between their origin and that of dentate granule cells for several reasons.  
Much of the same phenomena presented herein have been previously observed through 
the use of cultured hippocampal neurons in our laboratory (data not shown).  However, 
for techniques requiring large amounts of cells such as analysis of neurite outgrowth via 
IamgeXpress or immunoblot assay the use of hippocampal cultures is not ideal due to the 
48 
 
relatively low yield of each preparation.  Additionally, as sprouting in response to injury 
as well as seizure activity has also been observed within the cortex (Salin et al., 1995), I 
feel that the use of cortical neurons in these experiments does not present a significant 
problem. 
2.5. Transfection of cortical neuron cultures 
Neurons were transfected with various cDNA’s via Lipofectamine 2000 
(Invitrogen) per the manufacturer’s instructions.  Briefly, transfection reagent and 
cDNA’s were separately incubated in a serum-free media base (Neurobasal) (Invitrogen) 
for 5 min.  Mixtures were combined and incubated for 25 min.  The combined reagent 
mixture was added to cells in a drop-wise manner.  Cultures were returned to normal 
culture conditions (37°C, 5% CO2) for 3-4 h, at which point transfection reagents were 
fed off with normal media 
.2.6. Immunocytochemistry 
Cortical neuron cultures were washed with sterile PBS, fixed with 4% 
paraformaldehyde for 20 min at RT, and permeabilized with 0.2% TritonX-100 for 10 
min at RT.  Neurons were then pre-incubated in 10% bovine serum albumin (in PBS) for 
1 h at RT to block nonspecific binding.  Primary antibodies (diluted in BSA) (Table 2.2) 
were applied for 2 h at RT. Neurons were washed with PBS and fluorescently-conjugated 
secondary antibodies (Alexa-fluor 488 or Alexa-fluor 650) (diluted 1:500 in PBS) were 
applied to the cells for 30 min in RT.  Following another PBS wash, coverslips were 
mounted onto microscope slides with Prolong Antifade Gold mounting media + DAPI 
(Molecular Probe).  Neurons were imaged on Nikon Eclipse 90i microscope.
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Figure 2.1.  Composition of neuronal cultures.  Cortical neurons (7 DIV) 
immunostained for PSD-95 to reveal excitatory neurons, NF-200 to reveal 
neurons, GFAP to reveal astrocytes, and GAD67 to reveal inhibitory neurons.  
Scale bar: 50 µm. 
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2.7. Sholl analysis 
Neurite outgrowth of cortical neurons, transfected with enhanced green 
fluorescent protein (EGFP), CRMP2-EGFP, CRMP2 siRNA + EGFP, or CRMP25ALA-
EGFP was assessed as previously described (Wang et al., 2010a).  Cortical neurons were 
transfected at 9 DIV and maintained for an additional 48 h before fixation and imaging.  
Any treatment ((R)-LCM or VGSC inhibitors) occurred at 24 h post-transfection and 
lasted 18-24 h.  Sholl analysis was performed with ImageJ software using an automated 
Sholl analysis plug-in, in which the soma boundary is approximated by an ellipsoid, and 
neurite intersections are assessed at radial distances (20 µm increments) from the soma.  
Transfection of EGFP into neurons allowed optical identification and unequivocal 
determination of their arborizations.  No attempt was made to distinguish between axons 
and dendrites in the Sholl analysis.  However, using immunocytochemistry with a 
dendritic marker, MAP2, dendrites could be selectively identified (Figure 2.2).  Images 
were acquired with a Nikon Eclipse 90i microscope by an experimenter blinded to 
transfection/drug conditions.  Images were acquired across 3 separate culture wells.   
2.8. siRNA knockdown of CRMP2 
Validated small interfering RNAs (siRNAs) against the rat CRMP2 (5′-
ACTCCTTCCTCGTGTACAT-3′) sequence (Nishimura et al., 2003) and controls 
(scrambled sequence with approximately the same percentage of GC but no sequence 
homology) were used for CRMP2 knockdown (Invitrogen) in cortical neurons as 
described (Brittain et al., 2009, Chi et al., 2009, Brittain et al., 2011a, Brittain et al., 
2011b).  Cortical neurons were transfected with either control or CRMP2 siRNA, as well 
as EGFP to allow visualization.  Following transfections, neurons were maintained an  
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Figure 2.2.  Distinction of cortical neuron axons and dendrites.  Cortical neurons 
transfected with EGFP at 5 DIV and immunostained for MAP-2 at 7 DIV to identify 
dendrites.  Scale bar: 50 µm.   
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additional 48 h prior to imaging.  As neuronal transfection rates are relatively low (10-
15%), it is difficult to observe siRNA knockdown via western blot analysis.  Therefore, a 
neuronal progenitor cell line was used to verify siRNA knockdown of CRMP2.   
Cathecholamine A Differentiated (CAD) cells were grown in Ham’s F12/EMEM 
medium (Gibco) supplemented with 8% fetal bovine serum (Sigma) and 1% 
penicillin/streptomycin at 37°C and 5% CO2.    CAD cells were transfected with CRMP2 
or control siRNA (250 nM) and maintained for an additional 48 h, at which time extent of 
knockdown was assessed via immunoblot analysis.  As reported previously (Chi et al., 
2009), we observed a loss of CRMP2 immunoreactivity following knockdown of CRMP2 
compared to control siRNA (Figure 2.3).  Knockdown of CRMP2 with this siRNA has 
also previously been verified in cultured neurons via immunocytochemistry 
(Brustovetsky et al., 2014). 
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Figure 2.3.  siRNA knockdown of CRMP2.  Levels of 
CRMP2 and tubulin in CAD cells following 48 h 
incubation in control- or CRMP2-siRNA (250 nM).   
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2.9. Co-Immunoprecipitations 
Lysates were generated from post-natal day 1 (PN1) rat brains using lysis buffer 
composed of RIPA #1 buffer (see table X) and protease inhibitors.  Lysates were 
incubated in either DMSO (< 0.01%) or (R)-LCM (3, 30, or 300 µM) for 30 minutes, at 
which point they were incubated overnight in primary antibody against CRMP2 (Table 
2.2).  The antibody-captured complexes were recovered with fresh protein A agarose 
beads (30 µl, 50% slurry in RIPA #1) by incubation with lysate-antibody mixture for 2 h 
at 4°C.  Beads were then washed three times with lysis buffer and processed for 
immunoblot assay. 
2.10. Immunoblot assay 
Protein samples were boiled in Laemmli sample buffer for 5 min and fractionated 
on 4-15% separating SDS polyacrylamide gels.  Apparent molecular weights were 
determined using broad range standards (Fisher).  Following electrophoresis, proteins 
were transferred to PVDF membranes (Invitrogen) for immunoblotting.  Membranes 
were occasionally stained with ponceau (BioRad) to monitor transfer efficiency.  
Following transfer, membranes were blocked for 1 h in 5% skim milk powder + 0.05% 
BSA in TBST (Table 2.1) at RT.  Primary antibody incubations (see Table 2.2 for 
antibody information) were either 2 h at RT or overnight at 4°C.  Membranes were 
extensively washed in TBST and incubated in secondary antibody (goat anti-rabbit, goat 
anti-mouse, or donkey anti-sheep IgG horseradish peroxidase (HRP)) (G Biosciences) or 
(goat anti-rabbit, goat anti-mouse IgG dylight 650 or 800 conjugated) (Pierce) (1:15,000).  
Membranes incubated with HRP-conjugated secondary antibodies were washed 
extensively in TBST prior to probing with Enhanced Chemiluminescence Western 
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blotting substrate (Fisher) before exposure to photographic film.  Blots were exposed for 
a range of durations to ensure the generation of a print in which the film is not saturated.  
Membranes incubated with dylight-conjugated secondary antibodies were washed 
extensively in TBST prior to imaging with the LI-COR Odyssey imaging system.  Both 
images obtained from film and LI-COR were digitized and quantified using Un-Scan-It 
gel V6.1 scanning software (Silk Scientific Inc, Orem), limiting our analysis to the linear 
range. 
2.11. Turbidimetric assay for tubulin polymerization 
Polymerization of tubulin was performed as described previously (Chae et al., 
2009) with modifications.  This assay is based on the principle that light is scattered by 
microtubules to an extent that is proportional to the concentration of microtubule polymer 
(Shelanski et al., 1973, Lee and Timasheff, 1977).  Polymerization was performed in 0.1 
M G-PEM buffer (Table 2.1), 1 mM Na-GTP (Sigma), and 2 mg/ml tubulin 
(Cytoskeleton, Inc).  CRMP2 proteins (0.2 µM) as well as 3 µM (R)-LCM or 0.01% 
DMSO were added to the samples and pipetted onto a 96-well plate at 37°C.  Turbidity 
changes were assessed at 340 nm using a Viktor V3 spectrophotometer (Perkin Elmer, 
Indianapolis, IN), which had previously been pre-warmed to 37°C.  Absorbances were 
measure over time and compared to background samples which contained only buffer + 
GTP. 
2.12. Synaptic bouton size 
Synaptic bouton size was determined as previously described (Brittain et al., 
2009).  Briefly, cultured cortical neurons (6 DIV) were exposed to (R)-LCM (100 µM) or 
DMSO (< 0.01%) for 24 h.  Presynaptic terminals were loaded with the fluorescent styryl  
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Table 2.2. Antibodies Used 
Protein Dilution Source Epitope Applications Company Cat # 
CDK5 1:500 Rabbit 
Whole 
Protein 
WB, ICC 
Cell 
Signaling 
2506S 
CRMP2 1:1000 Rabbit 476-493 WB, IP Sigma C2933 
CRMP2 
(pSer522) 
1:500 Rabbit 
Phospho-
peptide 
WB, ICC 
ECM 
Biosciences 
CP2191 
CRMP2 
(pThr509/514) 
1:500 Sheep 504-517 WB Kinasource PB-043 
GSK3β 1:500 Rabbit 
Whole 
Protein 
WB Millipore PK1111 
GSK3β (pSer9) 1:500 Rabbit 
Phospho-
peptide 
WB Millipore 07-835 
GFAP 1:500 Mouse 411-422 ICC NeuroMab N206A/8 
MAP-2 1:500 Mouse 
Whole 
Protein 
ICC AbCam Ab2832 
NF200 1:350 Rabbit 
Whole 
Protein 
ICC Sigma N4142 
P35 1:500 Rabbit 
C-
terminal 
peptide 
WB 
Cell 
Signaling 
C64B10 
PSD-95 1:500 Mouse 77-299 ICC Neuromab K28/43 
Tubulin (βIII) 1:2000 Mouse 373-378 WB, ICC Promega G7121 
WB: western blot, IP: Immunoprecipitation, ICC: Immunocytochemistry 
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dye N-(3-triethylammoniumpropyl)-4-(6-(4-(diethylamino)phenyl) hexatrienyl) 
pyridinium dibrodmide (FM4-64; 15 µM) by incubation in a depolarizing tyrode’s 
solution (Table 2.1) for 1 min.  Cells were then washed with Ca2+-free solution with 
advasep-7 (200 µM; Biotinium, Inc.) to quench dye not taken up by endocytosis.  Nerve 
terminals were identified under a confocal microscope (Nikon Livescan SFC inverted 
microscope) using an oil-immersion CFI Plan APO VC x60 objective lens (Nikon).  
Fluorescence of the FM4-64 dye was excited at 543 nm and terminals capable of dye 
uptake were considered functional release sites.  Bouton size was determined by outlining 
the fluorescent puncta in regions of interest (ROI) using NIS Elements software (Nikon).  
The area of each ROI was then determined. 
2.13. Glutamate release 
Glutamate release from cultured cortical neurons was determined as previously 
described (Wang et al., 2010b).  Cultured cortical neurons (6 DIV) were exposed to (R)-
LCM (3, 30, 100 µM) or DMSO (< 0.01%) for 24 h.  Cells were washed three times with 
a non-depolarizing Tyrodes buffer (Table 2.1).  Following the third wash, 150 µl of each 
sample was collected and boiled for 5 min.  Release was then stimulated by incubating 
cells in a depolarizing Tyrode’s buffer (Table 2.1), at which point 150 µl was collected 
and boiled.  A second basal measurement was obtained by re-incubating in the non-
depolarizing buffer.  The remaining content was determined by incubating cells in the 
non-depolarizing buffer with 2% Triton X-100 (Sigma) to release intracellular glutamate.  
Total content was determined to be the sum of the basal, stimulated, second basal, and 
remaining samples.  Glutamate content in each sample was determined using the Amplex 
Red glutamic acid/glutamate oxidase assay kit (Invitrogen), where L-glutamic acid is 
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oxidized by glutamate oxidase to produce α-ketoglutarate, NH2, and H2O2.  The reaction 
between the Amplex Red reagent and H2O2 is catalyzed by horseradish peroxidase to 
generate the fluorescent product resorufin.  Fluorescence was measured in a Victor2 V 
multilabel plate reader (PerkinElmer) via excitation at 530 nm and emission at 590 nm 
and compared to a standard curve. 
2.14. ImageXpress neurite outgrowth 
Primary cortical neurons plated on 96-well culture plates were transfected via 
lipofectamine 2000 (Invitrogen) with EGFP, control siRNA +EGFP, or CRMP2-siRNA + 
EGFP at 4 DIV 48 h before imaging with ImageXpress Micro (Molecular Devices).  
Immediately prior to imaging, media was exchanged with sterile phosphate buffered 
saline (PBS).  The overexpression of EGFP allowed for visualization of a small 
percentage of neurons while maintaining optimal cell densities required for survival.  
EGFP fluorescence was imaged at 4x magnification.  To enable laser-based autofocus, 
laser offset was determined via z-stack.  Optimum exposure time was determined to 
prevent saturation.   
Analysis of neurite outgrowth was completed using a neurite outgrowth analysis 
protocol within the MetaXpress software (Molecular Devices).  Cell soma and processes 
are detected by defining separate size and fluorescence intensity threshold parameters. 
Maximun width and minimum area parameters for determining somas were set to 50 µm 
and 300 µm
2
, respectively.  For identifying processes, maximum width and minimum 
length parameters were set to 8 µm and 3 µm, respectively.  Cells were excluded if they 
were determined not to be neurons based on morphology, if processes extended beyond 
the image field, or if no processes were longer than 50 µm.  The following parameters are 
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recorded and summarized into a final “total outgrowth” parameter: number of processes, 
number of branches, mean process length, and maximum process length. 
2.15. Whole-cell patch-clamp recordings 
Whole-cell voltage recordings were performed at RT on primary cultured cortical 
neurons (7 DIV) using an EPC 10 Amplifier (HEKA Electronics).  Electrodes were 
pulled from thin-walled borosilicate glass capillaries (Warner Instruments) with a P-97 
electrode puller (Sutter Instrument) such that the final electrode resistances were 2-3 MΩ 
when filled with internal solutions.  Composition of internal and external recording 
solutions can be found in Table 2.1.  Whole-cell capacitance and series resistance (70-
80%) were compensated with the amplifier.  Cells were considered only when the seal 
resistance was more than 1 GΩ and the series resistance was less than 10 MΩ. Linear 
leak currents were digitally subtracted by P/4. 
2.16. Oxygen-glucose deprivation (OGD) 
Cortical neurons cultured in 96-well plates were exposed to OGD as previously 
described (Lei et al., 2006).  To allow visualization, cortical neurons were transfected 
with EGFP at 8 DIV and maintained for 48 h.  At 10 DIV, cultures were washed with 
sterile PBS and imaged using the ImageXpress system to obtain a “pre-OGD” image.  
Immediately following imaging, cells were returned to normal media conditions.  
Cultures were then placed in an anaerobic chamber (ThermoForma) containing 5% CO2, 
10% H2, 85% N2. The culture medium was replaced with deoxygenated, glucose-free 
BSS (Table 2.1).  The chamber was humidified and maintained at 37°C, and cells were 
exposed to the OGD condition for 2 h. OGD was terminated by returning the cultures to 
the normal medium and standard incubator. In some experiments, (S)-LCM (200 µM) 
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was applied after OGD. Twenty-four hours after OGD, cultures were washed into sterile 
PBS and imaged on the ImageXpress system to obtain a “post-OGD” image.   
2.17. Traumatic brain injury (TBI) 
All procedures involving animals were approved by the Institutional Animal Care 
and Use Committee of Indiana University School of Medicine and were carried out 
according to NIH guidelines and regulations.  Animals were doubly-housed and 
maintained in a 12 h light/12 h dark cycle environment with access to foor and water ad 
libitum.  Adult male Sprague Dawley rats (275-300 g) were subjected to controlled 
cortical impact (CCI) injury.  Rats were anesthetized with a ketamine/xylazine mixture 
(80 mg/kg and 5 mg/kg, respectively) and placed in a stereotaxic frame prior to TBI.  
Using sterile procedures, the skin was retracted, and a ~ 4 mm craniotomy was performed 
approximately 3 mm lateral to midline and 3 mm posterior to the bregma suture.  The 
skullcap was removed without disruption of the dura.  The impacting tip  (3 mm) was 
angled on a medial-lateral plane so that it was perpendicular to the exposed cortical 
surface.  The deformation impact depth was set a 1.5 mm, and the piston velocity was 
controlled at 3.0 m/s.  Following impact, the exposed tissue was covered with bone wax 
(Henry Schein) and the midline incision was sutured with 5.0 monofilament (Ethicon).  
Following surgery, animals received a bolus of sterile saline and post-operative analgesic 
Buprenorphine (0.5 mg/kg).  During all surgical procedures and recovery, the core body 
temperature of the animals were maintained at 36-37°C.  Sham animals received the same 
craniotomy and post-operative care.   
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2.18. Tissue processing for immunoblot 
At 24 h or 4 wk post-TBI, animals were sacrificed and transcardially perfused 
with 0.1 M phophate buffer (Table 2.1).  For perfusion, an incision is made in the left 
ventricle to allow insertion of a needle attached to a peristaltic pump through the ventricle 
and into the ascending aorta.  The needle was clamped into position and a second incision 
was made in the right atrium for drainage.  Following perfusion, brains were extracted 
and hippocampi ipsilateral and contralateral to the injury site were dissected, frozen in 
liquid nitrogen, and stored at -80°C.  Prior to immunoblot assay, tissue was thawed and 
homogenized using a sonicator.   
2.19. Activity dependent neurite outgrowth 
To elicit activity-dependent neurite outgrowth, cultured cortical neurons were 
exposed to 25 mM KCl (Tan et al., 2013) or vehicle (< 0.01% sterile saline) beginning at 
2 DIV.  At 4 DIV, neurons were transfected with EGFP to allow visualization.  As the 
transfection process results in a complete replacement of media, when feeding off 
transfection 25 mM KCl or vehicle was again included in the media.  For determining the 
involvement of CRMP2, cultures also received 200 µM (S)-LCM or 200 µM (S)-LCM + 
25 mM KCl at the previously mentioned time points.  Outgrowth was assessed 48 h post-
transfection (6 DIV). 
2.20. In vivo administration of (S)-LCM 
To provide continuous infusion, (S)-LCM was delivered via an implanted osmotic 
mini-pump (Alzet).  To compensate for animal growth over the 4-week treatment period, 
the animals were weighed prior to surgery and the amount of (S)-LCM was adjusted to 
account for the expected weight gain and an infusion rate of 2.5 µl/h to allow for 
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administration of an average of 5 mg/kg per day of (S)-LCM or < 0.01% DMSO for 
vehicle.  Immediately following CCI surgery, sterile mini-pumps were subcutaneously 
implanted.  An incision was made on the back, between the shoulder blades.  A small 
pocket was created by carefully separating skin from muscle near the incision site.  The 
mini-pump was placed into the pocket and the incision was closed with 5.0 
monofilament. 
2.21. Tissue processing for TIMM staining 
At 4 w following TBI, animals were sacrificed and transcardially perfused (as 
previously described) with a sodium sulfide perfusate solution (Table 2.1), followed by 
4% paraformaldehyde.  Following perfusion, brains were extracted and placed in 4% 
paraformaldehyde for 24 h at 4°C.  Brains were then transferred to 0.1 M phosphate 
buffer + 30% sucrose for 48 h at 4°C.  Tissue was embedded into Optimal Cutting 
Temperature (OCT) compound (Tissue-Tek) on dry ice.  Coronal slices (35 µm 
thickness) were made on a cryostat (Leica).  Slices were mounted onto gelatin-coated 
microscope slides and stored at -20°C.   
2.22. TIMM staining 
Tissue sections were allowed to thawed and processed for TIMM staining with 
the RAPID TIMM Stain Kit (FD Neurotechnologies).  Tissue sections were washed in 
0.1 M phosphate buffer 3 times, 3 min each and transferred to the TIMM solution (Table 
2.1), where they were rocked gently in the dark for 45-60 min at 30°C.  Sections were 
then rinsed in ddH2O for 3 min in the dark, followed by gently washing them in running 
water for 30 min to remove excess stain.  Sections were dehydrated in 50%, 75%, and 
95% ethanol for 3 minutes each.  Sections were incubated in absolute ethanol 3 times, 3 
63 
 
min each and then cleared in xylene (Fisher) 3 times, 3 min each.  Coverslips were added 
using a resinous mounting medium (Aquamount) (Fisher).   
 Once slides had dried, stained sections were imaged on a light microscope 
(Nikon) at 4x and 10x magnification.  Images focused on the dentate gyrus of the 
hippocampus.  TIMM staining was quantified using a previously established scoring 
system (Figure 2.4)  Briefly, images were given a score between 0 and 5, with 0 
accounting for a complete lack of TIMM granules within the supragranular zone and 5 
describing sections with a dense, laminar band of TIMM granules within the inner 
molecular layer. 
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Figure 2.4.  Scoring scale for evaluation of TIMM staining.  Figure 2 from 
Cavazos, Golarai, and Sutula.  Mossy fiber synaptic reorganization induced by 
kindling: time course of development, progression, and permanence.  Journal of 
Neuroscience. 1991 (Cavazos et al., 1991).  Distribution of TIMM granules in the 
supragranular region (black arrow) was rated on a scale of 0-5 based on the 
following criteria: 0, no reactivity in the supragranular region; 1, sparse granules in 
the supragranular region in a patchy distribution; 2, more numerous granules in the 
supragranular region in a continuous distribution; 3, prominent granules in the 
supragranular region in a continuous pattern; 4, prominent granules in the 
supragranular region that form a dense laminar band; 5, confluent dense laminar 
band of granules within the supragranular region that extends into the inner 
molecular layer. 
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CHAPTER 3. DEVELOPMENT OF A NOVEL TOOL TO TARGET CRMP2 
FUNCTION 
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3.1 Introduction 
The antiepileptic drug lacosamide ((R)-LCM) has been heralded as having a “dual 
mode of action” due to its proposed ability to bind CRMP2 in addition to the voltage-
gated sodium channel (VGSC) (Beyreuther et al., 2007).  However, opposing reports 
suggest that the action of (R)-LCM on CRMP2 is indirect (Wolff et al., 2012).  Therefore, 
the ability of (R)-LCM to directly interact with CRMP2 and impact its function remained 
controversial.  If (R)-LCM were able to selectively target CRMP2-mediated neurite 
outgrowth, it would be an extremely valuable tool in understanding the contribution of 
CRMP2 in the network reorganization commonly observed in TLE. 
3.2 Binding of (R)-LCM to wildtype but not mutant CRMP2 
Using the novel technique of microscale thermophoresis (MST), potential binding 
between (R)-LCM and CRMP2 was investigated.  MST employs the movement of 
proteins induced by microscopic temperature gradients to measure interactions between 
ligands and target proteins.  Thermophoretic movement away from the field of interest is 
indicated by a drop of fluorescence (Figure 3.1A).  Binding of other proteins, peptides, or 
small molecules alters the hydration shell, resulting in a change in thermophoretic 
movement (Wienken et al., 2010).  Primary-amine labeled CRMP2 was incubated with 
varying concentrations of (R)-LCM (0.009-150 µM and 0.03-1000 µM, respectively).  
Standard capillaries (Monolith NT Capillaries, NanoTemper) were filled with ~5 µl of 
sample mixture and thermophoresis analysis was performed on a NanoTemper Monolith 
NT.115 instrument.  MST curves were fitted using GraphPad Prism software to obtain 
relative Kd values.  Thermophoresis of labeled CRMP2 was altered by increasing
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Figure 3.1.  Binding of (R)-LCM to wildtype but not mutant CRMP2 in solution.  (A) Representative microscale thermophoresis (MST) 
curve.  A standard capillary containing NT647-labeled protein is locally heated by an IR laser (green arrow). Labeled protein diffuses away from 
the heated spot, causing a local depletion and drop in fluorescence.  Fluorescence returns following cessation of the IR laser (red arrow).  
Dashed blue lines indicate the point at which the degree of thermodiffusion is measured. (B, E).  MST time traces of wildtype CRMP2 and (R)-
LCM (0.009-150 µM) (B) and CRMP25ALA and (R)-LCM (0.030-1000 µM).  Thermodiffusion of CRMP2 but not CRMP25ALA was altered by 
increasing concentrations of (R)-LCM.  (C, F) Logarithmic dose-response curve used to determine the dissociation constant of (R)-LCM to 
fluorescently labeled CRMP2 (C) or CRMP25ALA (F).  Values represent mean ± SEM from 3 separate trials.  (D) CRMP2 surface representation 
highlighting the location of the (R)-LCM binding pocket (green).  The box represents an enlarged view of the binding pocket highlighting the 
helices and beta-strands (gold) involved in coordinating (R)-LCM binding.  The mutated residues comprising CRMP25ALA are indicated in single 
amino acid letter code.   
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concentrations of (R)-LCM, indicating an interaction with an apparent Kd value of 
approximately 1µM (Figure 3.1B-C).  In previous work using molecular modeling, 
cavities in the CRMP2 structure were identified that could coordinate LCM binding 
(Wang et al., 2010a).  A quintuplicate CRMP2 mutant (CRMP25ALA), harboring alanine 
mutations within the highest affinity LCM-binding pocket of CRMP2 (Figure 3.1D) was 
created using site-directed mutagenesis (Wang et al., 2010a).  These mutations did not 
alter the protein’s ability to mediate neurite dynamics, as the level of neurite complexity 
in the CRMP25ALA mutant overexpressing neurons was not different from wildtype 
CRMP2-overexpressing neurons.  Unlike wildtype CRMP2, thermophoresis of labeled 
CRMP25ALA was not affected by (R)-LCM, even at concentrations as high as 1mM 
(Figure 3.1E-F).  The lack of association with CRMP25ALA suggests both that the ability 
of (R)-LCM to alter thermophoresis of wildtype CRMP2 is not due to non-specific 
binding and that the interaction between (R)-LCM and CRMP2 is coordinated by the 
binding pockets previously identified via in silico docking. 
3.3 (R) LCM impairs neurite outgrowth, independent of actions on VGSC 
While (R)-LCM may preferentially bind CRMP2, it is not known if it can alter its 
function.  As CRMP2 is a positive regulator of neurite outgrowth, I tested the effect of 
300 µM (R)-LCM on neurite complexity in CRMP2-overexpressing cortical neurons.  
While this concentration is well above the required concentration for modulation of 
sodium channel function, it was chosen as a starting point as (R)-LCM’s interaction with 
CRMP2 remains poorly classified.  In order to assess the degree of neurite growth and 
branching I employed Sholl analysis on cortical neuron cultures overexpressing EGFP or 
CRMP2-EGFP.  This technique measures the number of neurites crossing concentric 
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circles (denoted as intersections or branch points) at various radial distances from the cell 
soma (Sholl, 1953).  This consecutive-circles (cumulative intersection) analysis specifies 
dendritic geometry, ramification richness, and dendritic branching patterns.  Cortical 
cultures were transfected with EGFP or CRMP2-EGFP at 9 DIV and analyzed 2 days 
following transfection.  Consistent with its canonical role, overexpression of CRMP2-
EGFP led to a significant increase in neurite complexity compared to EGFP 
overexpression (Figure 3.2).  In order to determine the effect of (R)-LCM on this 
phenomenon, 300 µM (R)-LCM was applied overnight to CRMP2-EGFP overexpressing 
cells 24 h following transfection.  Application of 300 µM (R)-LCM completely blocked 
the CRMP2-induced increase in neurite complexity (Figure 3.2A-B).  To address the 
possibility that the observed reductions in neurite complexity were due to the effects of 
(R)-LCM on voltage-gated Na+ channels, we repeated the morphological experiments in 
the presence of classical VGSC channel blockers which do not target CRMP2 including 
carbamazepine (300 µM), lidocaine (200 µM), or tetrodotoxin (100 nM).  No significant 
changes in neurite complexity were observed following these treatments (Figure 3.2C), 
suggesting the mechanism for the reduction in the neurite outgrowth is independent of 
(R)-LCM’s effect on voltage-gated sodium channels. 
3.4. Concentration-response of (R) LCM on neurite outgrowth 
To further characterize the effect of (R)-LCM on CRMP2-mediated neurite 
outgrowth, concentration-response curves were completed in CRMP2-EGFP and EGFP 
over-expressing neurons.  At 24 h following transfection, varying doses of (R)-LCM were 
administered overnight and the effect on neurite branching/outgrowth was analyzed 
(Figure 3.3A).  IC50 values for inhibition of neurite complexity were obtained by  
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Figure 3.2.  CRMP2-mediated neurite outgrowth is blocked by (R)-LCM.  (A) 
Representative inverted black and white images of cortical neurons 48 h after transfection 
with EGFP or CRMP2–EGFP.  Scale bar = 50 µm.  (B) Neurite complexity was calculated 
by Sholl analysis of cultured cortical neurons transfected at 9 DIV (and grown for 48 h).  
Peak numbers of intersections were observed at 275 µm from the soma.  Significant increase 
in neuritic complexity was seen in CRMP2-EGFP neurons (*, p <0.05 vs.  EGFP at each 
distance between 250–700 µm; Student’s t- test).  Overnight application of 300 µM (R)-
LCM in CRMP2-EGFP overexpressing neurons returned neuritic complexity to levels 
comparable to EGFP-overexpressing neurons.   At least 17 neurons were analyzed, in a 
blinded manner for each condition.  (C) Summary of the average peak neurite complexity for 
EGFP and CRMP2-EGFP transfected neurons treated with vehicle (0.01% DMSO), 300 µM 
(R)-LCM, 300 µM carbamezapine (CBZ), 200 µM lidocaine (LDC) or 100 nM tetrodotoxin 
(TTX).  To allow direct comparison, peak # of intersections are represented as a percentage 
of CRMP2-EGFP + DMSO.  (values represent mean ± SEM) (n= 15-25 for each condition) 
(*, p < 0.05 versus CRMP2-DMSO; one-way ANOVA, Bonferroni post-hoc analysis.)   
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Figure 3.3.  (R)-LCM causes a dose-dependent reduction in neurite outgrowth.  Sholl 
analysis of cortical neurons overexpressing CRMP2-EGFP (A) or EGFP (C) and treated for 24 
hr with 0.3 µM to 300 µM (R)-LCM or 0.1% DMSO (control).  To allow direct comparison of 
the effect of (R)-LCM between CRMP2-EGFP and EGFP expressing cells, number of 
intersections was normalized to the maximum number of intersections in each experiment.  
Arrow in A denotes the peak number of intersections, which occurred at ~275 µm radial 
distance from the soma.  Logarithmic dose-response plots of mean peak # of intersections for 
CRMP2-EGFP (B) and EGFP (D) transfected neurons.  Average peak # of intersections, 
obtained from the Sholl analyses, values were normalized to the average peak # of intersections 
in the vehicle (DMSO)-treated condition.  The IC50 for inhibition of neurite complexity by (R)-
LCM was determined by fitting the curve to a Sigmoidal dose response function (values 
represent mean ± SEM) (n= 15–25 cells for each condition from at least 3 separate culture 
wells). 
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comparing  the number of intersections at ~275 µm from the soma, as this was the 
relative distance at which the number of intersections peaked.  For neurons 
overexpressing CRMP2-EGFP, the IC50 of neurite inhibition was observed at 3.5 ± 1.7 
µM (R)-LCM (Figure 3.3B).  In contrast, in cells overexpressing EGFP, the calculated 
IC50 was 25.7 ± 1.9 µM LCM (Figure 3.3C-D).    While kinetic models predict that over-
expression should not alter potency, the output measured in these experiments (neurite 
outgrowth/branching) is not a binary reaction.  It is assumed that in our calculations, only 
a proportion of branching is CRMP2-mediated under naïve conditions.  However, in 
CRMP2-overexpressing cells, a larger proportion of branching is attributable to CRMP2 
and can, therefore, be targeted by (R)-LCM.  It is unlikely that differences in IC50 values 
reflect separate actions of LCM.   
3.5. Loss or mutation of CRMP2 impairs the effect of (R)-LCM on neurite outgrowth 
To verify that the ability of (R)-LCM to reduce neurite outgrowth is attributed to 
its interaction with CRMP2, experiments were repeated in neurons overexpressing 
CRMP25ALA.  Despite the enhanced neurite complexity seen following overexpression of 
CRMP25ALA (Figure 3.4A-B), the IC50 value for inhibition of neurite complexity by (R)-
LCM was calculated to be 25.7 ± 1.8 µM, almost exactly that of EGFP-overexpressing 
neurons (Figure 3.4C-D), suggesting that (R)-LCM is only targeting endogenous CRMP2 
in this system.  The inability of (R)-LCM to target CRMP25ALA- mediated enhancement 
of outgrowth demonstrates that the effect is specific to (R)-LCM’s interaction with 
CRMP2.  To further verify the specificity of (R)-LCM’s effect on neurite outgrowth, we 
repeated the aforementioned experiments following knockdown of endogenous CRMP2.  
Sholl analysis was performed 48 h post-transfection with CRMP2 siRNA + EGFP.  As  
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Figure 3.4.  Inhibition of neurite outgrowth by (R)-LCM following mutation of putative 
(R)-LCM binding sites within CRMP2.  (A,B) Sholl analyses of neurons expressing 
CRMP2 or CRMP25ALA.  Mutation of the LCM coordinating residues does not impair the 
ability of this mutant protein to promote neurite complexity.  (C) Sholl analyses of neurons 
expressing CRMP25ALA and incubated in varying concentrations of (R)-LCM as indicated.  
(D) Logarithmic concentration-response plot of mean peak # of intersections for CRMP25ALA 
expressing neurons.  The IC50 for inhibition of neurite complexity by (R)-LCM was 
determined by fitting the curve to a Sigmoidal dose response function (values represent mean 
± SEM) (n=15-25 cells per condition from at least 3 separate culture wells). 
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expected, the loss of CRMP2 expression reduced overall  neurite outgrowth.  Overnight 
application of 300µM (R)-LCM did not lead to a further reduction in neurite complexity 
(Figure 3.5).   
3.6. (R) LCM impairs CRMP2-enhanced tubulin polymerization 
The ability to bind and promote tubulin polymerization is necessary for CRMP2’s 
role in neurite outgrowth and branching (Charrier et al., 2003).  To investigate the 
mechanism behind the effect of (R)-LCM on CRMP2-mediated neurite dynamics, the 
amount of tubulin binding to CRMP2 was determined in the presence and absence of (R)-
LCM.  Co-immunoprecipitations were performed with a polyclonal CRMP2 antibody 
from postnatal day 1 rat brain lysates following 30 min incubations in either DMSO or 
(R)-LCM.  Co-immunoprecipitation of tubulin with CRMP2 was not altered by 
incubation of 3, 30, or 300 µM (R)-LCM (Figure 3.6A-B). 
Distinct from its ability to bind tubulin, CRMP2 has been shown to accelerate 
tubulin polymerization by enhancing the GTPase activity of tubulin (Chae et al., 2009).  
To determine if this process was altered in the presence of (R)-LCM, microtubule 
polymerization was measured via a turbidimetric assay.  Purified tubulin and recombinant 
CRMP2 or CRMP25ALA were combined in a glycerol-PEM buffer in the presence of 
DMSO or 3 µM (R)-LCM.  Increases in tubulin polymerization were determined by 
measuring absorbance at 340 nm every 30 seconds.  To compare overall changes in 
tubulin polymerization, the area under the curve was calculated for each condition, using 
the first 5 measurements from the naïve condition (tubulin alone) as a baseline.  
Consistent with previous reports, addition of CRMP2 enhanced tubulin polymerization 
(Chae et al., 2009).  Importantly, CRMP25ALA also led to a similar enhancement.  Co- 
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Figure 3.5.  siRNA knockdown of CRMP2 reduces neurite outgrowth.  (A) Sholl analysis 
of neurons transfected with control or CRMP2 siRNA  ±  300 µM (R)-LCM.  (B) To allow 
direct comparisons, the number of intersections were compared at ~200 µm from the soma, as 
this was that point at which intersections peaked, and expressed as a percentage of max.  The 
siRNA knockdown of CRMP2 decreased neurite outgrowth compared to control siRNA.  
Overnight incubation of 300 µM (R)-LCM did not cause a further decrease in complexity.  
(values represent mean ± SEM) (*, p < 0.05; One-Way ANOVA, Bonferroni post-hoc 
analysis). 
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Figure 3.6.  (R)-LCM reduces CRMP2-enhanced tubulin polymerization.  (A) Co-
immunoprecipitation of tubulin with CRMP2 in the presence of 3, 30 or 300 µM (R)-LCM 
compared to 0.1% DMSO (control).  (B) (R)-LCM treatment did not affect the amount of 
tubulin co-immunoprecipitated with CRMP2 as determined by densitometric analysis (data 
represents arbitrary densitometric units, n = 4).  (C) Effects of CRMP2 and CRMP25ALA 
recombinant proteins on microtubule assembly were measured by light scattering and 
absorbance at 340 nm.  Similar levels of tubulin polymerization were facilitated by CRMP2 
and CRMP25ALA proteins.  Inclusion of (R)-LCM (3 µM) with the CRMP2 protein caused a 
greater reduction in tubulin polymerization compared to similar treatment of the CRMP25ALA 
protein.  Also shown is the basal tubulin self-polymerization in the absence of any CRMP2 
(no CRMP2).  Background absorbance was subtracted from each experiment.  (D) Average 
area under the curve (AUC) values calculated from the tubulin polymerization curves shown 
in C.  Addition of 3 µM (R)-LCM led to a significant reduction in the tubulin polymerization 
AUC for wildtype CRMP2 (*, p < 0.05; One-Way ANOVA, Bonferroni post-hoc analysis).  
There was no statistical difference in the tubulin polymerization AUC for CRMP25ALA in the 
absence or presence of (R)-LCM (p > 0.05, One-Way ANOVA, Bonferroni post-hoc analysis) 
(values represent mean ± SEM) (n = 3-4). 
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application of 3 µM (R)-LCM prevented CRMP2- mediated enhancement of 
polymerization (Figure 3.6C-D).  (R)-LCM failed to prevent CRMP25ALA-mediated 
enhancement of polymerization as the trending effect of (R)-LCM did not reach 
significance.  In the absence of CRMP2 protein, tubulin polymerization was not altered 
by as much as 300 µM (R)-LCM (1.3 ± 0.5) versus naïve (0.4 ± 0.1; n=3, p> 0.05, 
Student’s t-test).  These results show that the effect of (R)-LCM is specific to CRMP2-
mediated enhancement of tubulin polymerization. 
3.7. (R) LCM does not alter synaptic bouton size or release of glutamate 
As it has previously been demonstrated that increased CRMP2 expression leads to 
an associated increase in synaptic bouton size (Brittain et al., 2009), the impact of (R)-
LCM on this parameter was investigated.  Styryl (FM) dyes enable the detection of 
presynaptic vesicle recycling and release (Ryu et al., 2008, Brittain et al., 2011a).  
Functional presynaptic terminals were loaded with FM4-64 (15 µM) by stimulating with 
90 mM KCl, followed by unloading in a Ca
2+
-free solution.  The area of FM4-64 labeled 
presynaptic terminals in cortical neurons was determined following overnight incubation 
of 100 µM (R)-LCM, compared to .01% DMSO.  Exposure to this level of (R)-LCM, 
sufficient enough to result in maximum reduction of CRMP2-mediated neurite 
outgrowth, did not alter bouton size (Figure 3.7A-B).  As CRMP2 is also a positive 
regulator of voltage-gated calcium channel function and subsequent neurotransmitter 
release, the effect of (R)-LCM on glutamate release was also investigated.  Importantly, 
overnight exposure to (R)-LCM did not affect glutamate release from cortical neurons 
stimulated with high K
+
 (90 mM) compared to 0.01% DMSO (Figure 3.7C-D).  These  
  
78 
 
  
Figure 3.7.  (R)-LCM does not alter synaptic bouton size or glutamate release.  (A) FM4-
64 loading of synaptic boutons in cortical neurons.  Arrows denote representative boutons.  
(B) Overnight treatment with 100 µM (R)-LCM did not affect bouton area. (p > 0.05, 
Student’s t-test).  (C) Glutamate release from cortical neurons following overnight treatment 
with 3 µM, 30 µM, and 100 µM LCM compared to 0.1% DMSO (control).  Data are 
represented as percent of total glutamate content.(D) Evoked glutamate release following (R)-
LCM treatment did not differ from control condition, where evoked release represents: 
(Stimulated-Basal) as a percent of total glutamate content. (p > 0.05, one-way ANOVA, 
Bonferroni post-hoc analysis) (values represent mean ± SEM). 
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results provide further evidence that (R)-LCM is preferentially targeting the ability of 
CRMP2 to mediate neurite outgrowth. 
3.8. (S) LCM retains the ability to bind CRMP2 
While (R)-LCM demonstrates potential in targeting CRMP2-mediated neurite 
outgrowth, its use a tool to determine the role of CRMP2 in mossy fiber sprouting is 
hindered by its action on the VGSC.  Interestingly, as the (S) isomer of lacosamide 
(formerly SPM 6953) requires much higher concentrations to halt seizure activity in vivo, 
LCM is considered stereoselective (Andurkar et al., 1999, LeTiran et al., 2001).  It was 
unknown, however, if the (S) isomer retains the ability to impair neurite outgrowth via a 
direct interaction with CRMP2.  MST was used to determine if (S)-LCM could interact 
with recombinant CRMP2.  NT647-labeled CRMP2 protein was incubated with varying 
concentrations of (S)-LCM (0.006-100 µM) and apparent Kd values were obtained by 
fitting curves using the Hill method. MST experiments revealed that (S)-LCM bound to 
CRMP2 with an apparent Kd of 1.5 ± 0.01 µM (Figure 3.8A-B).  As it was previously 
demonstrated that mutation of 5 key residues within the CRMP2 protein resulted in the 
loss of (R) LCM binding, experiments were repeated in the presence of CRMP25ALA 
(Figure 3.8C).  MST experiments revealed that (S)-LCM also did not interact with 
NT647-labeled CRMP25ALA (Figure 3.8D), suggesting that the same binding pocket is 
necessary for coordinating both (R)- and (S)-LCM binding. 
3.9. 200 µM (S) LCM phenocopies siRNA knockdown of CRMP2 
Although (S)-LCM was shown to interact with CRMP2, it is imperative to 
determine the effect of this interaction on CRMP2 function.  Ideally, the effect of (S)-
LCM on neurite outgrowth should mimic that of siRNA knockdown of CRMP2 sans the  
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Figure 3.8.  (S)-LCM retains the ability to bind CRMP2.  (A) MST time traces of wildtype 
CRMP2 and (S)-LCM (0.006-100 µM).  (B) Logarithmic dose-response data used to 
determine dissociation constant between CRMP2 and (S)-LCM (values represent mean ± 
SEM from 3 separate trials).  (C) Surface representation depicting (S)-LCM docked in the 
previously identified binding pocket on CRMP2 (green).  (D) Logarithmic dose-response of 
MST data for CRMP25ALA and (S)-LCM MST. (values represent mean ± SEM from 3 separate 
trials). 
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Figure 3.9.  (S)-LCM inhibits neurite outgrowth similar to that of CRMP2 siRNA.  (A) 
Inverted black and white representative image of a cortical neuron 48 hr following EGFP-
transfected neuron.  (B-F) Representative tracings of neurons transfected with EGFP ± 
control siRNA, CRMP2 siRNA, 200 µM (S)-LCM, or CRMP2 siRNA + (S)-LCM.  (G) Total 
outgrowth of neurons transfected with EGFP, control siRNA, or CRMPsiRNA combined with 
24 hr (S)-LCM treatment (200 µM).  CRMP2 siRNA and (S)-LCM reduced outgrowth to a 
similar level.  Combination of CRMP2 and (S)-LCM did not produce a further reduction.  (H-
K) Comparison of the effects of CRMP2 siRNA and (S)-LCM on # of branches, # of 
processes, mean process length, and maximum process length. (*, p < 0.05 vs EGFP, one-way 
ANOVA, Tukey’s post-hoc analysis) (values represent mean ± SEM) (n = 86-320 cells, 8 
separate culture wells). 
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off-target effects on other CRMP2-dependent signaling pathways.  Therefore, outgrowth 
was measured from EGFP-transfected primary cortical neurons (Figure 3.9A-E)  using 
the ImageXpress Micro and MetaXpress software systems (Molecular Devices).  This 
analysis combines the following measurements: number of primary neurites, number of 
branches, mean process length, and maximum process length to determine a summary of 
total outgrowth per cell.  Consistent with previous reports (Wilson et al., 2012), siRNA 
knockdown of CRMP2 led to a ~ 37% decrease in total outgrowth (62.6 ± 4.5) compared 
to control (100 ± 6.6) (Figure 3.9G).  Importantly, neurite outgrowth was not altered by  
conrol siRNA (85.1 ± 5.6) (p > 0.05).  The effect of CRMP2siRNA was mimicked by 
overnight application of 200 µM (S)-LCM, which decreased total outgrowth by ~34% 
compared to control (66.2 ± 4.5) (p < 0.05).  Importantly, (S)-LCM was not able to 
provide a further reduction following CRMP2 knockdown [(71.3 ± 3.3) vs (62.6 ± 4.5)] 
(p > 0.05) (Figure 3.9G). Total outgrowth is a representative summary of the following 
parameters: number of branches, number of processes, mean process length, and 
maximum process length (Figure 3.9H-K), all of which, aside from mean process length, 
were reduced by both (S)-LCM and CRMP2 siRNA.  
3.10. (S)-LCM does not impact VGSC slow inactivation 
To ensure that (S)-LCM is unable to alter VGSC function at the concentration 
used to impair outgrowth, whole cell recordings were used to measure levels of slow 
inactivation.  Neurons were held at −100 mV, conditioned to potentials ranging from −10 
mV to +20 mV (in +10 mV increments) for 5 s, and then fast-inactivated channels were 
allowed to recover for 150 ms at a hyperpolarized pulse to −120 mV, and the fraction of 
channels available was tested by a single depolarizing pulse, to 0 mV, for 15 ms (Figure  
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Figure 3.10.  (S- LCM does not alter slow inactivation of voltage-gated sodium channels.  
(A) Voltage protocol for slow inactivation.  Currents were evoked by 5 s prepulses between -
100 mV and +20 mV and then fast-inactivated channels were allowed to recover for 1 s at a 
hyperpolarized pulse to -100 mV.  The fraction of channels available was determined by a 15 
ms test pulse at -10 mV.  (B) Representative peak Na+ currents, in response to a step to -10 
mV following a prepulse at -100 mV (black trace) and -50 mV (grey trace) in neurons in the 
absence (left) or presence (right) of 300 µM (S)-LCM. (C) Summary of steady-state slow 
inactivation curves for cortical neurons ± 300 µM (S)-LCM. (D) For comparison, the fraction 
of current available following a -50 mV prepulse is depicted.  (S)-LCM did not alter sodium 
channel steady-state slow inactivation in cortical neurons. ( p > 0.05) (Student’s t-test) (values 
represent mean ± SEM). 
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3.10A).  Addition of 300 µM (S)-LCM did not alter the onset or extent of slow 
inactivation (Figure 3.10B-D).  Therefore, the ability of (S)-LCM to impair neurite 
outgrowth is likely due to its interaction with CRMP2 and is independent of VGSC 
function. As the effect of (S)-LCM on neurite outgrowth phenocopies that of siRNA 
knockdown of CRMP2, it is thus positioned as a valuable tool for isolating this select 
function of CRMP2 in a given process.   
3.11. Lacosamide derivative screen 
Through a collaboration with the laboratory from which (R)-LCM was originally 
developed (Harold Kohn, Ph.D., University of North Carolina, Chapel Hill), several 
derivatives of (R)-LCM were available with varying effects on sodium channel function.  
In attempt to identify more compounds that were able to impact CRMP2-mediated 
neurite outgrowth without altering VGSC function, LCM derivatives that had previously 
exhibited poor efficacy in targeting VGSC slow-inactivation were examined for their 
ability to reduce neurite outgrowth (Table 3.1).  While both (R)-and (S)-LCM reduced 
neurite outgrowth compared to DMSO, neither of the 2 identified derivatives were 
effective.  Therefore, (S)-LCM is the most likely candidate for preferentiallyly targeting 
CRMP2 function. 
3.12. Discussion 
Despite the controversy surrounding the relationship between LCM and CRMP2, 
these results provide further support for a direct interaction.  It was demonstrated that 
LCM has a functional impact on CRMP2, reducing neurite outgrowth by impairing the 
ability of CRMP2 to enhance tubulin polymerization.  Intriguingly, (R)-LCM was able to 
impact CRMP2 function at concentrations below those required for effective 
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enhancement of sodium channel slow inactivation (Errington et al., 2008, Sheets et al., 
2008).  While (R)-LCM prevented the increase in neurite outgrowth following 
overexpression of CRMP2, its efficacy in EGFP-expressing neurons suggests it was also 
able to alter the function of  
endogenous CRMP2.  Differences in the potency of (R)-LCM in CRMP2-EGFP or 
EGFP-overexpressing neurons likely reflect the ability of (R)-LCM to target a larger 
percentage of the output measure (neurite outgrowth) under conditions of CRMP2 
overexpression. As the level of CRMP2 expression is increased, so will the proportion of 
outgrowth attributable to CRMP2 function.  That these morphological reductions were 
observed at concentrations of LCM lower than those reported as the clinical therapeutic 
plasma concentrations (40–80 μM) (Greenaway et al., 2010), further supports our 
hypothesis that (R)-LCM's mode of action involves CRMP2 in addition to its action on 
VGSCs.   
 The mechanism by which (R)-LCM impairs neurite outgrowth was demonstrated 
to be impairment of CRMP2’s ability to enhance tubulin polymerization.  The region on 
CRMP2 responsible for enhancing the GTPase activity of tubulin lies within residues 
480–509 (Chae et al., 2009).  As the binding pocket for (R)-LCM is in proximity to this 
domain (i.e. prime binding pocket residues: E360, S363, K418, I420, and P443) (Wang et 
al., 2010a), it is possible that the binding of (R)-LCM may decrease CRMP2-enhanced 
microtubule assembly by altering the accessibility of the GTPase accelerating domain of 
CRMP2 to its effectors.  Despite these promising findings, the use of (R)-LCM as a tool 
to investigate CRMP2-mediated neurite outgrowth as it relates to pathological conditions 
is limited.  As neuronal activity is an important element in many pathological processes,  
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Table 3.1 Lacosamide Derivatives 
Compound Structure 
Slow 
Inactivation 
IC50 (µM) 
Total 
Outgrowth 
(% of Vehicle) 
(R)-LCM 
 
85 81.6 ± 3.7* 
(S)-LCM 
 
>1000 66.2 ± 5.9* 
Derivative 1 
 
>2400 95.8 ± 4.3 
Derivative 2 
 
>1000 98.0 ± 4.5 
Slow inactivation IC50 values were obtained from previous reports (Wang et al., 2010c, Wang et 
al., 2011).  Total outgrowth represents outgrowth following a 24 h incubation in 300 µM of each 
compound.  For ease of comparison values were normalized to vehicle.  (*, p < 0.05 vs vehicle) 
(Student’s t-test) (values represent mean ± SEM) (n = 263-394 cells from 8 separate culture 
wells). 
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especially epileptogenesis, the impact of (R)-LCM on VGSC function may be a 
confounding factor.  Therefore, the identification of a lacosamide derivative, which 
retains the ability to act on CRMP2, but not the VGSC, was imperative.  Our findings 
indicate that the presumed “inactive analog” (S)-LCM is able to interact with CRMP2 
and impact its function similar to that of (R)-LCM but without affecting VGSC function.  
As neurite outgrowth is merely one facet of CRMP2 function, (S)-LCM can be used in 
place of genetic knockdown strategies to selectively study this process.   
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CHAPTER 4. DECREASED GSK3β PHOSPHORYLATION OF CRMP2 MAY 
DRIVE MORPHOLOGICAL CHANGES DURING THE EARLY PHASE 
FOLLOWING TBI 
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4.1. Introduction 
In regards to its outgrowth-promoting function, the activity of CRMP2 is 
regulated by phosphorylation state.  In the unphosphorylated form CRMP2 is considered 
active and thereby growth-promoting; however, upon phosphorylation by a variety of 
kinases, most notably GSK3β and CDK5, CRMP2 is rendered inactive (Arimura et al., 
2000, Brown et al., 2004, Cole et al., 2004, Arimura et al., 2005, Uchida et al., 2005, 
Yoshimura et al., 2005, Cole et al., 2006, Hou et al., 2009, Uchida et al., 2009).  
Tonically active under naïve conditions, GSK3β is inactivated following insults 
commonly associated with TLE such as TBI (Shapira et al., 2007, Dash et al., 2011, Zhao 
et al., 2012), hypoxia-ischemia (Sasaki et al., 2001, Endo et al., 2006, Xiong et al., 2012), 
and status epilepticus (SE) (Lee et al., 2012).  This inactivation of GSK3β may lead to an 
overall decrease in the level of phosphorylated (inactive) CRMP2, thereby promoting 
neurite outgrowth.   
4.2. GSK3β phosphorylation of CRMP2 under naïve conditions 
In order for inactivation of GSK3β to impact CRMP2 function, a proportion of 
CRMP2 must be phosphorylated by GSK3β under normal conditions.  To determine the 
extent of GSK3β phosphorylation of CRMP2, primary cultured cortical neurons 
following exposure to the GSK3β inhibitor Lithium Chloride (LiCl) (10 mM) or the 
protein phosphatase inhibitor okadaic acid (200 nM) for 18-24 h (Figure 4.1A).  Western 
blot analysis was performed with an antibody specific to phosphorylation at GSK3β 
phosphorylation sites on the CRMP2 protein (i.e. Thr509 and Thr514).  Importantly, 
CRMP2 appears to be phosphorylated by GSK3β under control conditions (Figure 4.1B-
C).  Prevention of dephosphorylation by okadaic acid increased phosphorylation by ~2- 
90 
 
  
Figure 4.1.  Phosphorylation of CRMP2 by GSKβ.  (A) Signaling cascade involved in 
changes in phosphorylation of CRMP2 by GSK3β.  Inactivation of GSK3β occurs following 
activation of Akt or exogenous exposures to lithium chloride (LiCl).  Dephopshorylation of 
CRMP2 by PP2A is prevented by exposure to okadaic acid (OA).  (B) Levels of GSK3β-
phosphorylated CRMP2 and total CRMP2 following 24 hr treatment with LiCl (10 mM) or 
OA (200 nM).  (C-D) Summary of western blot analysis of GSK3β-phosphorylated CRMP2 
and total CRMP2 levels in cortical neurons ± LiCl or OA (*, p < 0.05 vs Ctrl, one-way 
ANOVA, Dunnet’s post-hoc analysis) (values represent mean ± SEM) (n = 3). 
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fold (12.1 ±1.3) compared to control (6.6 ± 0.6), while lithium-mediated inhibition of 
GSK3β resulted in an ~90% loss of phosphorylation (0.6 ± 0.3) (p < 0.05) (Figure 4.1B-
C).  Levels of total CRMP2 protein remained unchanged (control: 0.31 ± 0.03; okadaic 
acid: 0.41 ± 0.05; and lithium chloride: 0.37 ± 0.03) (p > 0.05) (Figure 4.1D).  This data 
suggests that a proportion of CRMP2 is phosphorylated by GSK3β under normal 
conditions and loss of GSK3β activity dramatically reduces the amount of 
phosphorylated CRMP2.  GSK3β phosphorylation of CRMP2 appears to be dynamically 
regulated, as evidenced by active dephosphorylation under control conditions. 
4.3 GSK3β inhibition increases neurite outgrowth via CRMP2 
In regards to its ability to promote neurite outgrowth, phosphorylation by GSK3β 
effectively inactivates CRMP2.  Therefore, inactivation of GSK3β should be growth 
promoting.  EGFP-transfected cortical neurons were exposed to lithium chloride for 18-
24hrs to determine the effect of GSK3β inhibition on neurite outgrowth (Figure 4.2A).  
Immediately following exposure, neurons were imaged using the ImageXpress Micro 
system and neurite outgrowth was determined via the MetaXpress software system.  As 
expected, inhibition of GSK3β increased total outgrowth (154.5 ± 5.9) compared to 
controls (99.8 ± 4.0) (p < 0.05) (Figure 4.2B-D).  To ensure that the increase in 
outgrowth was in fact due to changes in CRMP2 activity, the experiment was repeated in 
the presence of (S)-LCM (200 µM).  As (S)-LCM alone decreases outgrowth, it was 
included in both lithium chloride and control conditions.  In the presence of (S)-LCM, 
LiCl only increased total outgrowth by ~15% (15.3 ± 5.1) compared to ~54% (54.9 ± 5.9) 
in the absence of (S)-LCM (p < 0.05) (Figure).  Importantly, the effect of (S)-LCM once 
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again mimicked that of CRMP2siRNA [(15.3 ± 5.1) vs (-8.0 ± 15.7)] (p > 0.05) (Figure 
4.2E).  
4.4. Increased neurite outgrowth following OGD is CRMP2-dependent 
By depriving primary cultured neurons of both oxygen and glucose, one can 
simulate the disruption of the supply of oxygen and nutrients to the brain during a stroke 
(Goldberg and Choi, 1993).  Similar to what is observed in whole-animal hypoxia-
ischemia models, in vitro oxygen glycose deprivation (OGD) induces inactivation of 
GSK3β via the PI3K/Akt cascade (Chong and Maiese, 2007, Ueno et al., 2012).  
Interestingly, OGD is also associated with an increase in axonal/dendritic elongation and 
branching (Piccini and Malinow, 2001, Lei et al., 2006), that is reduced by preventing the 
inactivation of GSK3β (Ueno et al., 2012).  To further verify the role of CRMP2 in 
neurite outgrowth mediated by GSK3β inhibition, EGFP transfected cortical neurons 
were exposed to OGD for 2 h followed by reperfusion with normal media containing 
either (S)-LCM (200 µM) or DMSO (< 0.01%).  To better compare the effect of OGD on 
outgrowth in the different conditions, neurons were imaged immediately prior to OGD to 
obtain a “pre-OGD” image as well as 24 h following reperfusion to obtain a “post-OGD” 
image (Figure 4.3A).  This method allowed comparison of the same neuronal population 
before and after insult.  Total outgrowth measured 24 h following reperfusion was 
increased by ~100% (207.6 ± 38.5) compared to before OGD (100 ± 10.5) (p < 0.05) 
(Figure 4.3B-C).  When (S)-LCM was applied during reperfusion, neurite outgrowth 
post-OGD (68.35 ± 18.8) did not differ from that measured pre-OGD (100 ± 10.5) (p > 
0.05) (Figure 4.3B-C), suggesting that OGD-induced neurite outgrowth is mediated by 
CRMP2.   
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Figure 4.2. Inactivation of GSK3β enhances neurite outgrowth in a CRMP2-dependent 
manner.  (A) Experimental timeline.  Cortical neurons were transfected with EGFP or 
CRMP2siRNA + EGFP at 4 DIV and exposed to vehicle (< 0.01% DMSO), LiCl (10 mM), 
(S)-LCM (200 µM), or LiCl + (S)-LCM for 24 hr starting at 5 DIV and imaged at 6 DIV.  (B) 
GSK3β signaling cascade.  (C) Representative tracings of neurons transfected with EGFP and 
exposed to LiCl, (S)-LCM, or both.  (Scale bar = 150 µm).  (D) Total outgrowth of neurons 
exposed to LiCl for 24 hr (*, p < 0.05, student’s t-test) (values represent mean ± SEM).  (E) 
Enhancement of outgrowth by LiCl under conditions of (S)-LCM treatment or CRMP2 
siRNA knockdown (*, p < 0.05 vs EGFP, one-way ANOVA, Dunnet’s post-hoc analysis) 
(values represent mean ± SEM) (n = 92-150 cells from 8 separate culture wells). 
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Figure 4.3. Increased neurite outgrowth following OGD is CRMP2-dependent.  (A) 
Experimental timeline.  Cortical neurons were transfected with EGFP at 8 DIV.  At 10 DIV 
cells were imaged to produce a “pre”-OGD image and then immediately exposed to OGD 
conditions for 2 hr.  Following a 24 hr period where cells were reperfused with normal media 
+ vehicle (< 0.01% DMSO) or (S)-LCM (200 µM), cells were imaged to yield a “post”-OGD 
image.  (B) Representative traces of EGFP-transfected neurons before (pre) and after (post) 
OGD ± (S)-LCM.  (Scale bar = 150 µm).  (C) Summary of neurite outgrowth before and after 
OGD ± (S)-LCM (*, p < 0.05 vs Pre-OGD, one-way ANOVA, Tukey’s post-hoc analysis) 
(values represent mean ± SEM on a per well basis) (n = 4-6 wells). 
95 
 
4.5. Loss of CRMP2 phosphorylation following TBI 
Evidence of increased Akt activation within the hippocampus as well as other 
regions has been observed following TBI (Zhang et al., 2006, Zhao et al., 2012).  
Corresponding to changes in Akt activity, levels of phosphorylated (inactive) GSK3β are 
also increased following TBI (Shapira et al., 2007, Dash et al., 2011, Zhao et al., 2012).  
To determine if changes in CRMP2 phosphorylation were the driving force behind the 
increased neurite outgrowth in the hippocampus in TLE-related insults, hippocampal 
tissue was collected at both early (24 h) and late (4 wk) phases following TBI.  
Consistent with previous reports, levels of phosphorylated (inactivated) GSK3β were 
increased in the early phase following TBI (1.31 ± 0.08) compared to sham controls (1.00 
± 0.05) (p < 0.05) (Figure 4.4A-B).  Importantly, total expression of GSK3β remained 
unchanged [(1.00 ± 0.11) vs (0.81 ± 0.12)] (p > 0.05) (Figure 4.4A-B).  The increase in 
GSK3β phosphorylation appeared to be transient, as levels did not differ at 4 wk 
following TBI (0.97 ± 0.12) compared to sham controls (1.00 ± 0.06) (p > 0.05) (Figure 
4.4C-D).   
Subsequent to the observed inactivation of GSK3β, levels of GSK3β-
phosphorylated CRMP2 were reduced in the early phase following TBI (0.52 ± 0.07) 
compared to sham controls (1.00 ± 0.13) (p < 0.05) (Figure 4.5A-B).  No change in total 
CRMP2 expression was observed [(1.10 ± 0.12) vs (1.00 ± 0.04)] (p > 0.05) (Figure 
4.5A-B).  Despite the observed transience of GSK3β inactivation, levels of GSK3β-
phosphorylated CRMP2 remained reduced in the late phase following TBI (0.62 ± 0.08) 
compared to sham controls (1.00 ± 0.09) (p < 0.05) (Figure 4.5 C-D).  These results 
suggest that there is an increased level of active (unphosphorylated) CRMP2 in both the  
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Figure 4.4. Changes in GSK3β phosphorylation following TBI.  (A) Western blots of 
phosphorylated and total GSK3β from hippocampal tissue 24 hr following TBI.  (B) 
Summary of GSK3β pSer9 and total GSK3β levels 24 hr following TBI. (Data is depicted as 
arbitrary densitometric units (A.D.U.)).  (C) Western blots of phosphorylated and total 
GSK3β from hippocampal tissue 4 wk following TBI.  (D) Summary of GSK3β pSer9 and 
total GSK3β levels 4 wk following TBI (*, p < 0.05 vs sham, Student’s t-test) (values 
represent mean ± SEM) (n = 4-5). 
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Figure 4.5. Changes in CRMP2 phosphorylation by GSK3β following TBI.  (A) 
Western blots of GSK3β-phosphorylated and total CRMP2 from hippocampal tissue 24 hr 
following TBI.  (B) Summary of CRMP2 pThr509/514 and total CRMP2 levels 24 hr 
following TBI (raw data represents protein of interest normalized to tubulin and further 
normalized to sham to allow for easy comparison) (data is represented as arbitrary 
densitometric units (A.D.U)).  (C) Western blots of GSK3β-phosphorylated and total 
CRMP2 from hippocampal tissue 4 wk following TBI.  (D) Summary of CRMP2 
pThr509/514 and total CRMP2 levels 4 wk following TBI.  Data was normalized to sham 
conditions for ease of comparison. (*, p < 0.05 vs sham, Student’s t-test) (values represent 
mean ± SEM) (n = 4-5). 
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early and late phases following TBI.  Interestingly, while the decrease in CRMP2 
phosphorylation at 24 h post-TBI is directly correlated with an inactivation of GSK3β, 
the sustained decrease observed at 4 wk post-TBI appears to be independent of changes 
in GSK3β activity. 
4.6. Discussion 
In order for changes in GSK3β activity to impact CRMP2 function, a balance of 
GSK3β-phosphorylated and unphosphorylated CRMP2 must be present.  Importantly, 
GSK3β phosphorylation of CRMP2 appears to be dynamically regulated in naïve 
neurons, as inhibition of GSK3β led to an almost complete loss of phosphorylation within 
24 hours.  Additionally, the increase in phosphorylation following okadaic acid exposure 
provides evidence for active dephosphorylation.  Therefore, changes in GSK3β activity 
can directly impact CRMP2 function.  Indeed, inhibition of GSK3β led to increases in 
neurite outgrowth in a CRMP2-dependent manner.  As inactivation of GSK3β in these 
experiments resulted from an exogenous source (LiCl), it was important to demonstrate 
the involvement of CRMP2 in GSK3β-associated neurite outgrowth under pathological 
conditions.  Outgrowth of cortical neurons following OGD, which is prevented by 
inhibition of PI3K, coincides with an increase in GSK3β phosphorylation by Akt (Ueno 
et al., 2012).  Through the use of the novel tool (S)-LCM, it was determined that neurite 
outgrowth following OGD was, in fact, dependent on CRMP2.   
 Given that inactivation of GSK3β has previously been demonstrated following 
TBI, decreased phosphorylation of CRMP2 may account for the changes in neurite 
elongation and branching observed within the hippocampus.  Our findings indicate that 
TBI leads to decreased GSK3β phosphorylation of CRMP2 at both 24 h and 4 wk post-
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injury.  As mossy fiber sprouting is considered a progressive process, the maintained loss 
of phosphorylation throughout later phases following injury is an important finding.  In 
contrast to early phases following TBI, the loss of GSK3β phosphorylation at 4 wk post-
injury is likely not attributed to a prolonged inactivation of GSK3β.  In fact, previous 
reports suggest that levels of Akt-phosphorylated GSK3β return to baseline within 14 
days (Dash et al., 2011).  These findings suggest that while CRMP2 may play an integral 
role in promoting neurite outgrowth both immediately following injury as well as in later 
phases, the mechanisms underlying the increase in CRMP2 activity during these phases 
may differ. 
  
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5. DECREASED CDK5 PHOSPHORYLATION OF CRMP2 MAY 
DRIVE MORPHOLOGICAL CHANGES DURING LATE PHASE FOLLOWING 
TBI 
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5.1. Introduction 
It has been suggested that epileptogenesis during the latent period following TLE-
related insults is mediated by kindling-like events (Sutula, 2004).  These events are 
driven by subclinical episodes of network synchronization.  As such, many of the 
involved-processes may be activity dependent.  Previous reports have demonstrated that 
total activity blockade is able to prevent the development of hyperexcitability following 
neocortical injury (Graber and Prince, 1999).  Neurite outgrowth in particular is highly 
responsive to changes in neuronal activity (Van Ooyen et al., 1995).  Recently, CRMP2 
was identified to be involved in activity-dependent neurite outgrowth of cerebellar 
granule cells (Tan et al., 2013).  Unlike other central neurons, cerebellar granule cells 
require slightly depolarizing conditions for survival in vitro.  Therefore, it is difficult to 
generalize this finding to other neuron populations within the central nervous system.  As 
such, it is not known if CRMP2 is involved in outgrowth induced by depolarization in 
neurons where it is not necessary for survival. 
5.2. Targeting CRMP2 prevents KCl-facilitated outgrowth 
To determine the involvement of CRMP2 in activity-driven neurite outgrowth, 
cortical neurons overexpressing EGFP were exposed to 25 mM KCl and maintained for 
96 h to ascertain the extent of activity dependent neurite outgrowth (Figure 5.1A).  This 
concentration of KCl was chosen as it has previously been used to investigated the role of 
CRMP2 in activity-dependent neurite outgrowth of cerebellar granule neurons (Tan et al., 
2013).  As expected, chronic depolarization with 25 mM KCl led to a ~43% increase in 
total neurite outgrowth (143.1 ± 11.5) compared to control (100 ± 6.6) (p < 0.05) (Figure 
5.1 B-C).  Notably, blockade of CRMP2-mediated neurite outgrowth by (S)-LCM was  
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Figure 5.1. Targeting CRMP2 prevents KCl-facilitated increase in neurite outgrowth.  
(A) Timeline of experimental procedures.  (B) Representative tracings of cortical neurons 
expressing EGFP and incubated for 96 h in vehicle (< 0.01% DMSO), 25 mM KCl, 200 µM 
(S)-LCM, or 25 mM KCl + 200 µM (S)¬-LCM.  Scale bar = 150 µm.  (C) Total outgrowth of 
cortical neurons exposed to 25 mM KCl in the presence or absence of 200 µM (S)-LCM (*, p 
< 0.05 vs vehicle, Student’s t-test) (values represent mean ± SEM) (n = 127-205 cells from 8 
separate culture wells). 
103 
 
sufficient to prevent activity dependent growth induced by KCl (68.4 ± 3.8 vs 61.7 ± 3.5) 
(p > 0.05) (Figure 5.1 B-C).  As our earlier data demonstrated that (S)-LCM is not 
affecting VGSC function in these neurons, these data suggest that activity-dependent 
neurite outgrowth is dependent on CRMP2.   
5.3. Activity reduces CRMP2 phosphorylation by GSK3β without affecting kinase 
activity 
As phosphorylation by GSK3β regulates the ability of CRMP2 to enhance neurite 
outgrowth, western blot analysis was used to determine the level of GSK3β-
phosphorylated CRMP2 following acute (30 min) and chronic exposure to KCl (96 h) 
(Figure 5.2A).  Both acute and chronic treatments with 25 mM KCl reduced the level of 
GSK3β-phosphorylated CRMP2 (8.9 ± 1.5 and 10.0 ± 1.5, respectively) compared to 
control (22.1 ± 3.5) (p < 0.05), while total CRMP2 expression did not change (Figure 
5.2B-D).  Therefore, exposure to KCl leads to increased levels of active, 
unphosphorylated CRMP2.   
To determine if the decrease in CRMP2 phosphorylation induced by KCl is due to 
decreased levels of GSK3β activity, the amount of Ser9-phosphorylated GSK3β was 
measured following KCl exposure (Figure 5.3A).  Interestingly, phosphorylation of 
GSK3β was unaffected by acute or chronic KCl exposure [(16.4 ± 3.1 and 17.1 ± 4.3) vs 
(18.7 ± 3.6)] (p > 0.05) (Figure 5.3B-C).  Additionally, total GSK3β expression remained 
unchanged (Figure 5.3D-E).  Similar to what was observed in the late phase following 
TBI, these results suggest that the decrease in GSK3β-phosphorylated CRMP2 is not 
attributed to a change in GSK3β expression or activity.  
104 
 
  
Figure 5.2. KCl-induced activity decreases GSK3β phosphorylation of CRMP2.  (A) 
Timeline of experimental procedures.  (B) Western blot of GSK3β-phosphorylated CRMP2 
(CRMP2 pThr509/514) and total CRMP2 from naïve cortical neurons compared to those 
exposed to KCl for 30 min or 96 hr.  (C-D) Summary of CRMP2 pThr509/514 and total 
CRMP2 following KCl exposure (*, p < 0.05 vs control) (One-way ANOVA, Tukey’s post-
hoc analysis) (values represent mean ± SEM) (n = 4). 
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Figure 5.3. KCl-induced activity does not alter GSK3β activity or expression.  (A) 
Timeline of experimental procedures.  (B) Western blot of inactivated (Ser9 phosphorylated) 
GSK3β from naïve cortical neurons compared to those exposed to KCl for 30 min or 96 hr.  
(C) Summary of GSK3β pSer9 levels following KCl exposure.  (D) Western blot of GSK3β 
levels from naïve cortical neurons compared to those exposed to KCl for 30 min or 96 hr.  
(E) Summary of GSK3β levels following KCl exposure.  Expression of GSK3β pSer9 or 
total GSK3β did not change following 30 min or 96 hr KCl treatment. (One-way ANOVA, 
Tukey’s post-hoc analysis) (values represent mean ± SEM) (n = 4). 
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5.4. Activity reduces CDK5 priming of CRMP2 
As previously mentioned, CRMP2 phosphorylation by GSK3β first requires 
phosphorylation by CDK5 at a downstream site (Ser522), which “primes” the protein for 
subsequent GSK3β phosphorylation (Figure 5.4B).  Therefore, western blot analysis of 
CDK5-phosphorylated CRMP2 (pSer522) was used to determine if the KCl-induced 
decrease in GSKβ phosphorylation is due to a reduction in CDK5 priming.  Both acute 
and chronic exposure to KCl decreased the level of CDK5-phosphorylated CRMP2 in a 
time dependent manner (11.7 ± 2.9 and 3.2 ± 1.7, respectively) compared to control (21.2 
± 1.5) (p < 0.05) (Figure 5.4C-D), suggesting that the activity-dependent decrease in 
GSK3β-phosphorylated CRMP2 can be attributed to decreased levels of CDK5-primed 
CRMP2.   
 As the CDK5 site on CRMP2 (Ser522) has been shown to be resistant to 
dephosphorylation (Cole et al., 2008), the involvement of protein phosphatases is 
unlikely.  CDK5 activity is primarily determined by the level of its cofactor p35 (Lee et 
al., 1996, Zhu et al., 2005, Hisanaga and Endo, 2010).  Further western analysis 
demonstrated that the loss of phosphorylation by CDK5 was not due to changes in 
expression of CDK5 or p35.  Levels of p35 remained consistent following KCl exposure 
(0.011 ± 0.001) compared to controls (0.011 ± 0.001) (p > 0.05) (Figure 5.5).  Similarly, 
levels of CDK5 protein were nearly identical in control neurons (0.0156 ± 0.0012) and 
those exposed to KCl (0.0156 ± 0.0004) (p > 0.05) (Figure 5.5).  Therefore, at this point, 
the mechanism underlying the change in CDK5-phosphorylated CRMP2 is unknown.  
Mechanisms by which CDK5 is regulated following neuronal activity are not well 
understood.
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Figure 5.4. KCl-induced activity decreases CDK5 phosphorylation of CRMP2.  (A) Timeline 
of experimental procedures.  (B) Diagram of GSK3β and CDK5 phosphorylation sites within the 
CRMP2 sequence.  (C) Western blot of CDK5-phosphorylated CRMP2 (CRMP2 pSer522) from 
naïve cortical neurons compared to those exposed to KCl for 30 min or 96 hr.  (D) KCl exposure 
led to a time-dependent decrease in the level of CRMP2 pSer522. (*, p < 0.05 vs control) (#, p < 
0.05 vs 30 min KCl treatment) (One-way ANOVA, Tukey’s post-hoc analysis) (values represent 
mean ± SEM) (n = 4-5). 
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Figure 5.5. KCl-induced activity does not alter expression of CDK5 or p35.  (A) 
Timeline of experimental procedures.  (B-C) Western blots of p35 and CDK5 levels from 
naïve cortical neurons compared to those exposed to KCl for 96 hr.  (D-E) Levels of p35 
and CDK5 expression were not altered following KCl treatment. (Student’s t-test) (values 
represent mean ± SEM) (n = 4-5). 
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5.5. “Primed” CRMP2 is decreased in the late, but not early phase following TBI 
As decreased levels of GSK3β-phosphorylated CRMP2 were observed following 
activity that were secondary, not to changes in GSK3β expression or activity, but rather 
decreased CRMP2 priming by CDK5, it is possible that changes in GSK3β-
phosphorylated CRMP2 observed in later phases following TBI may be attributed to a 
decrease in phosphorylation by CDK5.  Therefore, levels of CDK5-phosphorylated 
CRMP2 were assayed from hippocampal tissue collected at early (24 h) and late (4 wk) 
time points following TBI.  Notably, CDK5 phosphorylation of CRMP2 at 24hr 
following TBI did not differ from sham controls [(1.05 ± 0.07) vs ((1.00 ± 0.12)] (p > 
0.05) (Figure 5.6).  However, at 4 wk following injury, levels of CDK5-phopshorylated 
CRMP2 were decreased (0.69 ± 0.07) compared to sham controls (1.00 ± 0.03) (p < 0.05) 
(Figure 5.6).  These results suggest that CRMP2 is differentially regulated during early 
and late phases following injury.  While a loss of GSK3β activity accounts for decreases 
in CRMP2 phosphorylation immediately following injury, the same phenotype during 
later phases is attributed to a loss of priming by CDK5. 
5.6 Effects of targeting CRMP2 in vivo on mossy fiber sprouting 
As changes in CRMP2 phosphorylation, and presumably activity, are observed 
within the hippocampus at both early and late time points following TBI, CRMP2 may be 
involved in both the induction and maintenance of mossy fiber sprouting following 
injury.  To determine the importance of CRMP2 in this phenomenon, osmotic minipumps 
containing (S)-LCM (140 mg/kg) were implanted (subcutaneously) immediately 
following TBI surgery in adult male rats.  This method allowed for continuous delivery 
of approximately 5 mg/kg (~ 0.21 mg/kg per hour) (S)-LCM per day over the course of 4  
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Figure 5.6. Changes in CRMP2 phopshorylation by CDK5 following 
TBI.  (A) Western blots of CDK5-phosphorylared CRMP2 from 
hippocampal tissue 24 hr and 4 wk following TBI.  (B) Summary of 
CRMP2 pSer522 levels at both 24 hr and 4 wk following TBI.  For ease of 
comparison, data was normalized to the sham conditions.  Levels of 
CRMP2 pSer522 were decreased at 4 wk, but not 24 hr following TBI. (*, 
p < 0.05, student’s t-test) (values represent mean ± SEM) (n = 4-5). 
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weeks (Figure 5.7A).  At the cessation of treatment, bilateral hippocampal tissue was 
obtained and processed for TIMM staining, to reveal the extent of mossy fiber sprouting 
within the inner molecular layer.  Both low and higher magnification images were 
obtained using a light microscope (Nikon 90i) and scored by three observers blinded to 
the conditions, based on the scale originally established by Cavazos and colleagues 
(Cavazos et al., 1991).  Briefly, the scoring system ranks TIMM staining on a scale of 0-
5, with 0 being the absence of TIMM granules within the supragranular region and 5 
indicating the existence of a dense band of TIMM granules within supragranular region, 
extending into the inner molecular layer.  To avoid issues of variance among animals, 
scores were compared from contralateral and ipsilateral hippocampi from the same 
animal to yield the difference in TIMM scoring (Ipsilateral – Contralateral).   
As expected, TBI led to increased TIMM differences (1.40 ± 0.25) compared to 
sham controls (0.25 ± 0.25) (p < 0.05) (Figure 5.7B-D).  Importantly, differences in 
TIMM scores did not differ between sham (0.25 ± 0.25) and naïve animals (0.00 ± 0.32) 
(p > 0.05).  Intriguingly, (S)-LCM treatment prevented the TBI-induced increase in 
TIMM differences (0.40 ± 0.25) compared to animals receiving TBI alone (1.40 ± 0.25) 
(p < 0.05) (Figure).  However, the changes in TIMM scores following TBI did not differ 
between animals receiving (S)-LCM (0.40 ± 0.25) and vehicle (~0.01%DMSO) (1.00 ± 
0.00) (p > 0.05) (Figure 5.7C-D).  Therefore it cannot definitively be concluded that 
CRMP2 is necessary for mossy fiber sprouting following TBI.   
5.7. Discussion 
The multitude of contradicting reports concerning mechanisms underlying 
activity-dependent outgrowth may hint at the sheer complexity of this phenomenon.  It is  
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Figure 5.7. Effects of targeting CRMP2 in vivo on mossy fiber sprouting.  (A) 
Timeline of experimental design.  Animals received either controlled cortical impact or 
sham (craniotomy) surgery. Immediately following surgery, animals were implanted with 
osmotic mini-pumps containing either vehicle or (S)-LCM to be continuously infused at < 
0.01% DMSO and ~5 mg/kg per day.  Following 4 wk of treatment, tissue samples were 
prepared for histology. (B) (Left) Representative low-magnification image of a TIMM-
stained coronal section.  (Right) High magnification of highlighted region depicting the 
dentate hilus (DH), granule cells layer (GCL), and inner molecular layer (IML).  (C) 
Representative 10x-magnification images of ipsilateral and contralateral TIMM-stained 
hippocampi.  TBI led to a dense laminar band of TIMM reactivity within the 
supragranular zone extending to the inner molecular layer (black arrow).  (D) Summary 
of TIMM scores from animals exposed to sham or TBI surgery ± vehicle or (S)-LCM.  To 
minimize the impact of variance among animals, data is represented as the difference in 
TIMM score between ipsilateral and contralateral hippocampi from the same animal.  (S)-
LCM treatment prevented the TBI-induced increase in mossy fiber sprouting, however 
did not differ from vehicle. (*, p < 0.05 vs sham) (#, p < 0.05 vs TBI) (one-way ANOVA, 
Tukey’s post-hoc analysis) (values represent mean ± SEM) (n = 4-5). 
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likely that specific mechanisms may depend largely on a variety of factors including, but 
not limited to, cell type, developmental stage, type of stimulation, and axonal/dendritic 
distinction.  However, our findings, along with those of Tan and colleagues (Tan et al., 
2013), represent two separate reports of the involvement of CRMP2 in activity-driven 
neurite outgrowth in two distinct cell populations.  Specifically, KCl-driven activity led 
to changes in CRMP2 activity through regulation of its phosphorylation state.  
Interestingly, decreased levels of GSK3β-phosphorylated CRMP2 were observed 
following activity that were secondary, not to changes in GSK3β expression or activity, 
but rather decreased CRMP2 priming by CDK5.   
The mechanism underlying the change in CDK5-phosphorylated CRMP2 remains 
unknown.  As the CDK5 site on CRMP2 (Ser522) has been shown to be resistant to 
dephosphorylation (Cole et al., 2008), the involvement of protein phosphatases is 
unlikely.  Unfortunately, mechanisms by which the activity of CDK5 is regulated 
following neuronal activity are not well understood.  High levels of activity have been 
demonstrated to induce calpain cleavage of CDK5’s cofactor p35, creating p25, which 
contributes to increased CDK5 activity (Patrick et al., 1999, Kerokoski et al., 2004).  
However, as these events typically culminate in apoptosis-related cell death it is likely 
that such high levels of activity were excitotoxic in nature and the events following 
cannot be generalized to all neuronal activity.  Alternatively, activation of ionotropic 
glutamate receptors has been shown to induce auto-phosphorylation of the co-factor p35, 
thereby labeling it for proteosomal degradation and culminating in decreased CDK5 
activity (Wei et al., 2005).  This finding suggests that activity-dependent changes in 
CDK5 activity may be attributed to changes in p35.  However, as levels of p35 
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expression remained constant in our investigation, it is unlikely that the decrease in 
CDK5-phopshorylated CRMP2 is due to p35 degradation.  Similarly, work by Schuman 
and Murase suggests that neuronal activity driven by KCl depolarization leads to a 
decrease in CDK5 activity that is cofactor independent (Schuman and Murase, 2003).  
This work has since been corroborated in a report that demonstrated activity-dependent 
decreases in CDK5 activity that were p35 independent (Nguyen et al., 2007).  
Interestingly, protein kinase C (PKC) has been shown to decrease CDK5 phosphorylation 
of substrates without affecting kinase activity or cofactor expression (Sahin et al., 2008).  
Given the varying avenues that allow for regulation of CDK5, it is possible that the 
method by which CDK5 is regulated by activity may depend on a variety of factors, 
similar to that of activity-dependent neurite outgrowth.   
Mossy fiber sprouting in TLE can likely be divided into 2 distinct phases: the 
induction phase, during which sprouting and outgrowth are attributed directly to the 
precipitating insult such as TBI, hypoxia-ischemia, or status epilepticus, and the 
maintenance phase (Sutula, 2004, Pitkänen and Lukasiuk, 2009).  The latter phase 
involves processes secondary to the original insult such as hyperexcitability and network 
synchronization.  Consistent with theories implying that the progression of mossy fiber 
sprouting is mediated by activity-dependent mechanisms, our results revealed that the 
decrease in GSK3β-phosphorylated CRMP2 during later phases following injury was in 
fact attributed to a decrease in priming by CDK5.  In combination with changes in 
GSK3β activity that were observed during the early phase, phosphorylation of CRMP2 
appears to be differentially regulated through both induction (early) and maintenance 
(late) phases following traumatic brain injury.  As such, targeting CRMP2-mediated 
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neurite outgrowth throughout these stages may be sufficient to attenuate the progression 
of mossy fiber sprouting.  Indeed, the extent of mossy fiber sprouting in animals that had 
received continuous administration of (S)-LCM following TBI was markedly decreased 
compared to untreated animals.  However, the trending effect of vehicle administration is 
a confounding factor that prevents a definitive conclusion from being drawn.  The lack of 
significant separation between (S)-LCM- and vehicle-treated groups may be a result of 
the nature of administration, despite the previous success observed with infusion of (R)-
LCM in a separate study (Licko et al., 2013).  While continuous subcutaneous infusion 
was considered to be preferable over daily intraperitoneal injections, it is possible that 
inflammation at the implantation site may have been a factor.  The reduction in mossy 
fiber sprouting in (S)-LCM-treated animals suggests, at the very least, that CRMP2 may 
be one factor involved in initiation and progression of mossy fiber sprouting.  However, 
that the reduction in mossy fiber sprouting over vehicle-treated animals does not reach 
significance is indicative that more work is needed in order to definitively claim that 
increases in CRMP2 activity account for aberrant mossy fiber sprouting following TBI. 
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CHAPTER 6. DISCUSSION 
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6.1. Overview of Chapter 3 
Despite previous controversy concerning the proposed interaction between 
CRMP2 and (R)-LCM, MST data demonstrated that (R)-LCM binds to CRMP2 in 
solution.  Importantly, no association was detected between (R)-LCM and a CRMP2 
mutant in which the five key residues previously identified to coordinate (R)-LCM 
binding had been mutated to alanines (CRMP25ALA). Functional analyses revealed that 
(R)-LCM reduces neurite outgrowth in a CRMP2-dependent manner.  Notably, (R)-LCM 
was observed to directly impair the ability of CRMP2 to enhance tubulin polymerization.  
As (R)-LCM also enhances slow-inactivation of the VGSC, its use in studying CRMP2 
function within a complex system is limited.  However, the “inactive enantiomer” (S)-
LCM was discovered to retain its ability to bind CRMP2 despite no longer being able to 
impact VGSC function.  As no association could be detected between (S)-LCM and 
CRMP25ALA, it is assumed that the same binding pocket is responsible for coordinating 
both enantiomers on the CRMP2 protein.  Given that (S)-LCM mimics the effect of 
CRMP2 knockdown on neurite outgrowth, it serves as an acceptable tool for the study of 
a specific role (i.e., promotion of neurite outgrowth) of this multi-functional protein.  As 
many other CRMP2 functions such as regulation of voltage-gated calcium channels, 
neurotransmitter release, synaptic bouton size, and binding of tubulin were not affected 
by (R)-LCM, the assumption is made that these functions are also not altered by (S)-
LCM.  However, as this was not explicitly tested in my thesis work, it remains an 
assumption. 
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6.2. Overview of Chapter 4 
Under naïve conditions, CRMP2 was observed to exist in a balance of 
phosphorylated (inactive) and unphosphorylated (active) forms, allowing for dynamic 
regulation of its activity.  As a proportion of CRMP2 appears to be tonically 
phosphorylated by GSK3β, LiCl-induced inhibition of GSK3β resulted in a decrease in 
CRMP2 phosphorylation, thereby increasing the proportion of active (unphosphorylated) 
CRMP2 within the cell.  This increase in CRMP2 activity was translated into increased 
neurite outgrowth that was determined to be CRMP2-dependent.  Some neuronal insults 
(e.g., OGD) can lead to increased neurite outgrowth via inactivation of GSK3β.  Through 
the use of (S)-LCM, increased neurite outgrowth following OGD was also determined to 
be CRMP2-dependent.  As phosphorylation (inactivation) of GSK3β has been observed 
following TBI (Shapira et al., 2007, Dash et al., 2011, Zhao et al., 2012), I hypothesized 
that changes in CRMP2 activity could account for the mossy fiber sprouting induced by 
TBI.  Interestingly, levels of active (unphosphorylated) CRMP2 were increased in both 
the early and late phases following TBI.  The loss of GSK3β-phosphorylated CRMP2 
during the early phase is attributed to an observed increase in phosphorylation 
(inactivation) of GSK3β.  Consistent with previous reports (Dash et al., 2011, Zhao et al., 
2012), levels of phosphorylated GSK3β had returned to baseline by 4 wk post-injury.  
Therefore, the sustained loss of GSK3β-phosphorylated CRMP2 during the late phase is 
likely independent of changes in kinase activity. 
6.3. Overview of Chapter 5 
Neurite outgrowth, both under normal conditions as well as in response to injury, 
has previously been associated with activity-driven phenomena (Van Ooyen et al., 1995, 
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Overman and Carmichael, 2014).  As mossy fiber sprouting is also thought to involve 
activity-dependent processes (Sutula, 2004), I hypothesized that CRMP2 activity may be 
regulated by neuronal activity.  Indeed, neurite outgrowth induced by chronic KCl 
exposure was observed to be CRMP2-dependent.  The increase in outgrowth can be 
attributed to a dramatic decrease in GSK3β-phosphorylated CRMP2.  Similar to what is 
observed in the late phase following TBI, the decrease in GSK3β-phosphorylated 
CRMP2 was observed to be independent of kinase activity.  For some substrates of 
GSK3β (including CRMP2), phosphorylation of a nearby serine is required in order to be 
recognized and phosphorylated by GSK3β (DePaoli-Roach, 1984, Fiol et al., 1988).  In 
the case of CRMP2, it must be first be phosphorylated by the serine/threonine kinase 
CDK5 (Yoshimura et al., 2005, Cole et al., 2006).  Therefore, it was hypothesized that 
the activity-driven change in GSK3β phosphorylation of CRMP2 reflected a decrease in 
phosphorylation by CDK5, rather than a loss of GSK3β activity.  Indeed, exposure to 
KCl resulted in a time-dependent decrease in the level of CDK5-phosphorylated CRMP2.  
As this could not be explained by changes in the expression of CDK5 or its co-factor p35, 
the mechanism responsible for activity-driven changes in CDK5-phosporylated CRMP2 
remain unknown.  While changes in phosphatase activity may be involved in changes in 
GSK3β-phosphorylated CRMP2, the CDK5 site has proven to be extremely resistant to 
dephosphorylation (Cole et al., 2008).   
 As TBI can lead to progressive hyperexcitability (Yang et al., 2010a), it was 
hypothesized that the activity-driven decrease in CRMP2 priming by CDK5 might 
account for the prolonged loss of GSK3β-phosphorylated CRMP2 following TBI.  While 
there was no change in CDK5-phosphorylated CRMP2 in the early phase following 
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injury, levels were decreased during the late phase.  Therefore, phosphorylation of 
CRMP2 is differentially regulated throughout both phases following injury.  As a loss of 
phosphorylation would result in an overall increase in the amount of active CRMP2 
within the hippocampus, it was hypothesized that increased CRMP2 activity may play an 
important role in mossy fiber sprouting following injury.  To test this hypothesis, one 
must be able to preferentiallyly target the neurite outgrowth-promoting function of 
CRMP2, especially since CRMP2 has been shown to be involved in other TBI-related 
phenomena (Brittain et al., 2012).  As I had demonstrated that (S)-LCM can serve as a 
tool for the study of CRMP2-mediated neurite outgrowth in complex systems, it was 
administered to TBI-injured animals throughout the 4 wk following the injury.  While the 
TBI-induced increase in mossy fiber sprouting was effectively prevented in (S)-LCM-
treated animals, the extent of sprouting did not differ from vehicle treated animals.  Many 
factors may have contributed to the lack of significance observed over the vehicle-treated 
group including dose, route of administration (subcutaneous), and complications with 
minipump implantation.  Further work is needed to verify if CRMP2 activity is necessary 
for mossy fiber sprouting.   
6.4. Conclusion 
It was initially presumed that molecular cues supporting mossy fiber sprouting 
were triggered solely by the precipitating injury and would decline over time, thereby 
providing a “critical period” for the prevention of mossy fiber sprouting (Lew and 
Buckmaster, 2011).  However, use of the mTOR inhibitor Rapamycin has demonstrated 
that if administered for 2 months, which dramatically reduces sprouting, mossy fiber 
sprouting will return within 2-4 months (Buckmaster et al., 2009, Lew and Buckmaster, 
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2011).  These findings suggest that the signals underlying mossy fiber sprouting persist 
for months following injury.  A distinction is often made concerning the pathological 
events following traumatic insults, such as TBI.  Alterations initiated by the injury itself 
are often referred to as primary damage, while secondary damage refers to pathological 
processes such as neurodegeneration, gliosis, or angiogenesis which are more indirectly 
related to the precipitating injury (Hayes et al., 1998, Reilly, 2001, Faden, 2002, 
Thompson et al., 2005, Pitkanen et al., 2006, Pitkänen et al., 2009).  It may be necessary 
to make the same distinction of epileptogenesis.   
 Two separate theories exist concerning the development of epilepsy following 
injury: (1) the mechanisms underlying epileptogenesis are initiated by the precipitating 
injury yet are slow and progressive in nature (Mathern et al., 1996, Mathern et al., 2002).  
(2) Events directly caused by the initial injury are self-limiting, yet lead to a sequence of 
slowly-evolving phenomena which render the system vulnerable to the development of 
epilepsy (Sutula, 2004).  The first theory suggests that epileptogenesis is a direct result of 
primary damage, while the second theory suggests that it is secondary damage that is 
responsible.  The body of work presented here suggests that primary and secondary 
damages may not be mutually exclusive and that both may contribute to epileptogenic 
processes, such as circuit reorganization.  It has been demonstrated that early events 
following injury, such as decreased phosphorylation of CRMP2 by GSK3β, can be 
attributed to injury-induced mechanisms (i.e., activation of pro-survival pathways such as 
PI3K).  However, these events are transient in nature.  The sustained loss of CRMP2 
phosphorylation is likely due to progressive changes in neuronal function which are 
secondary to the precipitating injury, such as activity-driven changes in CDK5 function.  
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Although the exact role of CRMP2 in mossy fiber sprouting has not yet been determined, 
it is possible that the loss of GSK3β phosphorylation immediately following injury 
contributes to the induction of mossy fiber sprouting while the loss of priming by CDK5 
in later phases contributes to the maintenance of mossy fiber sprouting.  It is of great 
interest that these mechanistically distinct events culminate in a similar end-point: an 
increase in the amount of active CRMP2 (Figure 6.1).   
 At this point in time, however, a causal relationship has yet to be drawn between 
mossy fiber sprouting and epileptogenesis.  The variety of pathologies and methods 
employed to induce spontaneous recurring seizures suggests that epileptogenesis and the 
progression of epilepsy symptoms are unlikely to be characterized in simple terms 
(Sutula, 2004).  Prevailing theories suggest that mossy fiber sprouting likely in 
combination with other mitigating factors contributes to epileptogenesis.  At the very 
least, mossy fiber sprouting is linked to the exacerbation of the progression of the disease 
as well as the manifestation of its symptoms (Zhang et al., 2002).  The involvement of 
CRMP2 in such processes, however, remains unseen. 
123 
 
  
Figure 6.1.  Graphical summary of findings (A) GSK3β is phosphorylated and thereby 
inactivated in the early phases following injury.  This inactivation leads to decreased amounts of 
phosphorylated (inactive) CRMP2.  (B) CDK5 phosphorylation of CRMP2 is decreased in the 
later phases following injury.  This decrease in phosphorylation also indirectly reduces levels of 
GSK3β-phosphorylated CRMP2 through a loss of priming, resulting in an overall increase in the 
proportion of active CRMP2.  (C) The sustained increase in unphosphorylated (active) CRMP2 in 
the hippocampus may underlie aberrant mossy fiber sprouting following injury. 
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CHAPTER 7. FUTURE STUDIES 
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As with any body of scientific investigation, there are questions that remain 
unanswered.  If given the time and resources, I would explore the following areas: 
7.1. What is the mechanism underlying the activity-driven decrease in CDK5 
phosphorylation of CRMP2? 
As previously discussed, the mechanisms by which CDK5 is regulated in 
response to neuronal activity are widely unknown.  Contradicting studies report that 
activity-dependent changes in phosphorylation of CDK5 substrates is co-factor 
dependent/independent (Patrick et al., 1999, Schuman and Murase, 2003, Kerokoski et 
al., 2004, Wei et al., 2005, Nguyen et al., 2007).  If given the opportunity, I would repeat 
the experiments mentioned in section 5.4 in which cortical neurons were exposed to KCl 
for 96 h.  Lysates from these cells would then be used to perform in vitro kinase assays to 
determine if the CDK5 from neurons exposed to KCl is less active.  Additionally, I would 
use immunoblot assays to determine the level of less-widely studied co-factor, p39.  
Finally, co-immunoprecipitations would be performed to determine if the association of 
CDK5 to p35 or p39 was affected by KCl.  A decrease in co-factor binding may account 
for the decrease in substrate phosphorylation.   
 Once the mechanism for activity-driven regulation of CDK5 is determined, I 
would then determine if the same mechanisms were responsible for the loss of CDK5-
phosphorylated CRMP2 following TBI.  Unlike GSK3β, the involvement of CDK5 in 
injury-induced epileptogenesis has not been widely studied.  Contrary to my findings, 
phosphorylation of CDK5 substrates was observed to be increased in a chemical kindling 
model (Tian et al., 2010).  In this model the increase in phosphorylation was attributed to 
an increase in CDK5 mRNA and protein.  In support of my hypothesis, CDK5 activity 
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was observed to be decreased during the late stages of electrical kindling (Tomizawa et 
al., 2000).  In this report, however, decreased kinase activity was attributed to changes in 
expression of the co-factor, p35.  What is of most interest to my studies is what was 
revealed by immunohistochemistry.  The subcellular localization of CDK5 within the 
dentate gyrus was gradually altered throughout the kindling process.  Prior to kindling, 
CDK5 immunoreactivity was mainly observed within the dendrites and axons of dentate 
granule cells.  As kindling progressed however, CDK5 appeared to translocate to the 
soma as immunoreactivity in the processes decreased and somal expression increased.  
This finding raises a question as to the importance of recognizing phosphorylation 
changes within specific compartments (soma vs processes).  For example, although 
overall levels of CDK5 expression remained constant, the loss of CDK5 from the axon 
and dendrites would greatly affect phosphorylation of substrates within these 
compartments.  While CDK5-phopshorylated CRMP2 is observed within both the soma 
and processes (Figure 7.1), in which compartment phosphorylation occurs is at present 
unknown.   
7.2. Is CRMP2 necessary and sufficient to induce mossy fiber sprouting? 
The results gained from section 5.7 were unfortunately inconclusive.  Therefore, 
if given the opportunity I would like to repeat these experiments with some 
modifications.  I had originally planned to administer at least two different doses of (S)-
LCM following TBI; however, I was limited by the amount of the compound that was 
available to me.  It is my hypothesis that increasing the dose of (S)-LCM may provide 
clearer results.  Despite past success using osmotic minipumps, it may also be necessary  
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Figure 7.1.  Subcellular distribution of CDK5-phopshorylated CRMP2.  Cortical 
neurons (7 DIV) were immunostained for CDK5 or CRMP2 pSer522 along with tubulin to 
visualize the localization of each protein with the cell.  Scale bar: 50 µm. 
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to alter the route of administration.  The results from these experiments will answer to the 
necessity of CRMP2 in mossy fiber sprouting. 
 To determine if increased CRMP2 activity is sufficient to induce mossy fiber 
sprouting I would propose a transgenic approach.  Dentate granule cells express high 
amounts of the zinc transporter-3 (ZnT-3) compared to cells in surrounding areas.  
Therefore, it may be possible to use an inducible Cre system behind the ZnT-3 promoter 
to selectively overexpress a phospho-null mutant CRMP2 (CRMP2 T509A/T514A) 
within the dentate granule cells.  As this mutant cannot be phosphorylated by GSK3β, it 
should be constitutively active.  It is my hypothesis that the overexpression of active 
CRMP2 within the dentate granule cells will be sufficient to induce mossy fiber 
sprouting. 
7.3. What is the relationship between mossy fiber sprouting and epileptogenesis? 
Whether a causal relationship exists between mossy fiber sprouting and 
epileptogenesis  has long been under debate (Sutula, 2002).  This is perpetuated by the 
lack of a method for specifically targeting mossy fiber spouting in vivo.  Studies using 
rapamycin have published conflicting reports as to whether preventing mossy fiber 
sprouting impacts the development of spontaneous recurring seizures (Zeng et al., 2009, 
Huang et al., 2010, Buckmaster and Lew, 2011, Tang et al., 2012, Guo et al., 2013, Heng 
et al., 2013).  Many factors may contribute to the lack of success in this area.  Computer 
simulations have revealed that even a small amount of mossy fiber sprouting could 
potentially increase seizure susceptibility (Santhakumar et al., 2001, Dyhrfjeld-Johnsen et 
al., 2010).  Therefore, it may be necessary to completely ablate mossy fiber sprouting 
before an effect on epileptogenesis can be observed.  Additionally, as the target of 
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rapamycin, mTOR, is involved in numerous cellular processes, especially following 
injury, it is difficult to draw clear conclusions from its use in these studies.   
Assuming that the experiments proposed in the section above were successful, I 
would employ continuous-video EEG monitoring of animals receiving (S)-LCM 
treatment following TBI, as well as other models of acquired epilepsy.  If the relationship 
between mossy fiber sprouting and epileptogenesis is causal in nature, I would expect 
(S)-LCM treatment to decrease the frequency of spontaneous seizures, as well as increase 
the latency to the first seizure.  For further verification, it would be interesting to 
determine if inducing mossy fiber sprouting in vivo leads to the development of 
spontaneous seizures.  Using the aforementioned transgenic model, mossy fiber sprouting 
would be induced by overexpression of CRMP2 T509A/T514A within the dentate 
granule cells.  Continuous video-EEG monitoring would determine if the animals 
demonstrated epileptiform activity.   
At this point, it appears unlikely that mossy fiber sprouting is the only factor 
involved in epileptogenesis.  However, it also seems unlikely that is does not contribute 
to the epileptogenic process.  The most plausible explanation is that mossy fiber 
sprouting is one factor, which in combination with many others, may assist in the 
initiation and/or progression of epileptogenesis (Figure 7.2). 
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Figure 7.2.  Schematic representation of the interplay between factors proposed to 
contribute to epileptogenesis.  Adapted from O’Dell et al., Understanding the basic 
mechanisms underlying seizures in mesial temporal lobe epilepsy and possible therapeutic 
targets: a review.  Journal of Neuroscience Research. 2012.(O'Dell et al., 2012)   
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